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ABSTRACT In March 2015, a meeting was held in London, United Kingdom, to address the progress in 
targeting the unmet need for dry eye disease (DED) treatment. The meeting, which launched the i2 = 
initiating innovation series, was sponsored by the Tear Film & Ocular Surface Society (TFOS; 
www.TearFilm.org) and supported by Dompé. The TFOS i2 meeting was designed to review advances in 
the understanding of DED since publication of the 2007 TFOS International Dry Eye WorkShop (DEWS) 
report, and to help launch the highly anticipated sequel, DEWS II. The meeting was structured to discuss 
the scope of the DED problem, to review the clinical challenges of DED, and to consider the treatment 
challenges of DED. This article provides a synopsis of the presentations of this TFOS i2 meeting. 
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I. INTRODUCTION 
 
 The Tear Film & Ocular Surface Society (TFOS; www.TearFilm.org) sponsored its inaugural meeting of 
the i2 = initiating innovation series in March 2015 in London. This TFOS series will involve meetings 
addressing the unmet needs for a variety of ocular surface diseases. The London meeting was entitled 
“Targeting the Unmet Need for Dry Eye Treatment” and was designed to review progress in the 
understanding of dry eye disease (DED) since publication of the 2007 TFOS International Dry Eye 
WorkShop (DEWS) report.1 The meeting was approved by the TFOS Board of Directors, organized by Dr. 
David A. Sullivan, coordinated by Ms. Amy Gallant Sullivan (TFOS Executive Director), and attended by a 
number of individuals from Europe. The speakers, panelists, and moderators, who were invited by TFOS 
to participate, are shown in Table 1. The specific topics to be addressed were three-fold: first, to discuss 
the scope of the DED problem, including its epidemiology, iatrogenic induction, and contact lens 
association; second, to review the clinical challenges of DED, including its pathophysiology, 
symptomatology, and diagnosis; and third, to consider the treatment challenges of DED, including new 
pharmaceutical, device and surgical approaches for its therapy, as well as the regulatory issues 
associated with the development of a DED drug in Europe. This article summarizes the presentations of 
this TFOS i2 meeting. 
 
I. A. TFOS Mission (David A Sullivan, MS, PhD, FARVO) 
Dr. Sullivan opened the meeting by stating the mission of TFOS: To advance the research, literacy 
and educational aspects of the scientific field of the tear film and ocular surface. He thanked the invited 
speakers and panelists for their participation, Dompé for its generous financial support, and Ms. Sullivan 
for her excellent meeting coordination. Dr. Sullivan also noted that this i2 meeting would help launch the 
much-anticipated sequel of the original TFOS DEWS.1 This forthcoming Workshop, termed DEWS II, will 
soon begin, and will 1) update the definition, classification, and diagnosis of DED; 2) critically assess the 
etiology, mechanism, distribution, and global impact of this disorder; and 3) address its management and 
therapy. 
 
I.B. Treatment of Dry Eye Disease, an Unmet Need (Harminder Dua, MD, PhD) 
Dr. Harminder Dua presented a clinical scenario to illustrate the dilemma posed by DED: a patient 
presents to the specialist complaining of dry eyes. After a thorough evaluation (including detailed 
medical history, clinical examination, and diagnostic tests), the clinician confirms that the patient has dry 
eyes. This begs the question, is dry eye a symptom or a diagnosis? When used interchangeably it leads to 
confusion. Moreover, most available treatments target DED symptoms but do not address etiology. This 
problem is central to the unmet need in the treatment of DED, which Dr. Dua defined as six fundamental 
insufficiencies, summarized below. 
 
I.B.1.  A Universally Accepted Set of Criteria for Diagnosis 
The first unmet need is the ambiguity of whether “dry eye” represents a symptom or a diagnosis. 
From the patients' perspective, dry eye is a complaint (i.e., a symptom). The physicians use the term as a 
diagnosis. The connotation of the terms needs to be clarified and the symptom distinguished from the 
diagnosis by providing clarity in terminology. This is further complicated by the use of varying 
nomenclature to describe the condition (Table 2). 
Moreover, with the possible exception of tear osmolarity, tests used in the assessment of dry eye 
are notoriously nonpathognomic—lacking correlation between signs and symptoms—and have 
significant overlap between normal and abnormal values.2 Foremost among the unmet needs in dry eye 
treatment is a uniform concept and minimum set of criteria for diagnosis. Attaining this goal will facilitate 
the design and interpretation of clinical studies, and make the results more meaningful and easier to 
compare. 
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I.B.2.  Understanding the Global Magnitude of the Problem 
The 2007 TFOS DEWS Report thoroughly evaluated DED in its scope3 and therapeutic 
management.4 As one of the most frequent pathological conditions in ophthalmology, DED is a leading 
cause of patient visits to hospitals. Prevalence is as high as 50% (depending on criteria used), with more 
affected women than men. Prevalence is also higher in Asian and aging populations, though younger 
people are increasingly manifesting symptoms. There is a known disparity between patients requiring 
and receiving treatment, especially in Asian compared to Western countries, while figures for other 
regions are lacking. Thus, elucidating the true global magnitude of DED is another major unmet need in 
its management. 
 
I.B.3.  Understanding the Underlying Mechanisms of DED 
According to the British National Formulary (BNF),5 there are over 50 dry eye preparations in the 
UK alone, in addition to a variety of goggles, humidifiers, and other devices that deliver heat or massage 
to the lids. Despite the wide range of treatments available, an online survey conducted in March 2011 by 
Harris Interactive (commissioned by Allergan) found that of the respondents with symptoms of dry eye, 
69% had not seen an eye care professional, and of those who did, 22% did not experience relief of 
symptoms with treatment.6 As a potential contributing factor, many available treatments contain 
preservatives such as benzalkonium chloride (BAK or BAC, which has well-established toxic effects on the 
ocular surface) and disodium EDTA (a known irritant with potential epithelial toxicity).4 Moreover, most 
available treatments overlook the underlying pathology involving corneal nerves, which are increasingly 
being recognized as key players in the pathology of postoperative dry eye and visual aberrations. As they 
are a major basis of symptoms (and DED is primarily a symptom-driven disease), corneal nerves need to 
be specifically studied. A greater understanding of nerve alterations in DED is an unmet need.  
 
I.B.4.  Innovative Therapeutic Strategies Targeting the Underlying Biomechanics of DED 
There also is a great need for innovative therapeutic strategies that target the underlying 
biomechanics of DED. The innovation of lubricin,7, 8 a proteoglycan and boundary lubricant in the 
management of DED is one example in this context.  
 
I.B.5.  Integrated Pathways of Care and Universal Protocols for Managing DED 
As the world population is expected to increase from 7.2 billion in 2012 to between 8.3–10.9 
billion by 2050,9 the concern of DED is expected to rise. According to The Lancet Series on Ageing, 
published in 2014, 2 billion people will be aged 60 years or older by the year 2050,10 and assuming a 
prevalence of 25%, 500 million people will have the disease in this demographic alone. With 
approximately 19,000 ophthalmologists in the United States and just over 200,000 worldwide,11 DED 
represents a growing burden on the ophthalmic care system, with a high ratio of DED patients to 
ophthalmologists and sight-threatening eye diseases competing for attention. Thus, there is a need to 
integrate the entire ophthalmic workforce: ophthalmologists, general practitioners, optometrists, 
opticians, nurses, orthoptists, staff, and patients. This includes universally accepted and regionally 
tailored protocols for treatment and referral, with increased education, heightened awareness, and 
adequate training. 
 
I.B.6.  Integrated Prevention Strategies in the Management of DED. 
The 2007 report of the TFOS DEWS Epidemiology Subcommittee identified both modifiable and 
nonmodifiable risk factors for DED.3 Further study is needed to identify those at risk and influence 
modifiable risk factors. These advances will help integrate prevention and early intervention into the 
management of DED. 
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II. SCOPE OF THE DED PROBLEM 
II. A.  Epidemiology of DED (Kelly Nichols, OD, MPH, PhD) 
 
Dr. Kelly Nichols stated that the 2007 report of the TFOS DEWS Epidemiology Subcommittee was a 
significant advance in a developing field with limited published research, and presented three 
epidemiology-related goals: 1) to assess and summarize current knowledge on the epidemiology of DED 
(prevalence, incidence, natural history); 2) to describe the risk factors for DED; and 3) to summarize 
existing questionnaires for DED and make recommendations for the use of such surveys in clinical trials.3 
In the current meeting, Dr. Nichols reviewed progress in each of these areas since the 2007 report, and 
undertook multiple approaches to estimate growth in the area of ocular surface epidemiology: reviewing 
the published literature, reviewing trials registered at clinical trials.gov, and reviewing surveys utilized in 
clinical trials. 
 
II.A.1.   Advances in DED Epidemiology 
 
II.A.1.a.  Prevalence of DED 
 
The current global prevalence of dry eye can be assessed from available population-based studies, 
summarized in Table 3. At the time of 2007 report of the TFOS DEWS Epidemiology Subcommittee,3 only 
eight population-based epidemiologic studies of DED had been published, with prevalence ranging from 
5% to 30%.12-19 Based on data from the largest U.S. studies of adults over 50 years of age, the Women’s 
Health Study17 and the Physicians’ Health Study,19, 20 3.23 million women and 1.68 million men in the 
United States have mild-to-moderate or even severe symptoms of DED. The study in US women by 
Schaumberg and colleagues17 was notable in that it used a short survey of just three questions. 
By 2011, at least 7 additional population-based studies evaluating dry eye had been published,21-27 
generally using a symptom-based or a modified field-testing sequence. Prevalence ranged from 
approximately 5% to over 50%, which highlights the variation in how DED is defined in these studies. 
Several more recent studies have provided estimates of the current global prevalence of dry eye, 
28-38 with prevalence ranging from approximately 10% to 20% (again emphasizing the variability in 
defining DED). Prevalence tended to be higher in women compared to men. Studies conducted in Asian 
populations seem to indicate a higher prevalence of dry eye, and many of the studies have utilized similar 
symptom batteries as previously performed studies. The reasons for the higher prevalence values in Asia 
require further exploration. 
It is now widely accepted that the prevalence of DED increases with age; however, depending on 
the ethnicity of the population in question, the universal value of 15% over the age of 65, based on a 1997 
study by Schein et al.,12 may be an underestimate of actual ocular surface disease prevalence, especially in 
Asian populations. There remains a discrepancy between those who have received diagnoses of “dry eye” 
and those with mild-to-moderate or even severe symptoms. Moreover, with our increased scrutiny on the 
prevalence of anterior blepharitis and MGD relative to evaporative dry eye, the lines become increasingly 
blurred, and it has been suggested that MGD should be included in the definition of DED.39 Caution should 
be used in interpreting symptom-based diagnostic criteria, as multiple ocular surface and lid conditions 
can yield the same patient-reported symptoms. 
 
II.A.1.b.  Incidence of DED 
Regarding the incidence of dry eye (rate of new or newly diagnosed cases), 13.3% of subjects in 
the Beaver Dam Eye Study41 developed dry eye over five years, and 21.6% developed dry eye over 10 
years. The effect of age was relatively modest, and no difference between sexes was observed over a five-
year period. However, over a 10-year period, the incidence was significantly greater in women (25.0%) 
than men (17.2%). 
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II.A.1.c.  Natural History of DED 
Since the 2007 TFOS DEWS report, there has been little progress in understanding the natural 
history and progression of dry eye. Progression between severity groups has been assessed in one small-
scale study,42 and is currently under investigation by Allergan. A study by Bron et al. considered the 
progression of DED, and suggested that over time aqueous-deficient dry eye (ADDE) may develop 
features of evaporative dry eye (EDE) and vice versa.43 Overall, there remains an overall paucity of 
literature in this area. 
 
II.A.1.d. Risk Factors for DED 
The second major goal of the TFOS DEWS Epidemiology Subcommittee was to describe the risk 
factors for DED and grade them by level of evidence (mostly consistent, suggestive, or unclear).3 The 
Subcommittee recommended that “future studies of risk factors for dry eye should concentrate on the 
examination of biologically compelling hypotheses in a detailed fashion, with appropriate attention to all 
aspects of good epidemiological study design,” and that studies not designed to detect risk factors should 
be interpreted with caution. 
Since the 2007 TFOS DEWS report, additional risk factors have been identified. In a study of the 
long-term incidence of DED, increased incidence was associated with age, female gender, poorer self-
rated health, antidepressant or oral steroid use, and thyroid disease untreated with hormone; lower risk 
was associated with sedentary lifestyles or use of angiotensin-converting enzyme inhibitors.41 In men (an 
under-evaluated population), data from the US Physicians’ Health Studies suggested that risk factors for 
dry eye included benign prostatic hyperplasia (BPH), medications used to treat BPH, and antidepressant 
medications.20 Patients with DED have also been demonstrated to have a significantly higher prevalence 
of medical comorbidities (including depression, ischemic heart disease, hyperlipidemia, peripheral 
vascular disorders, migraines, myasthenia gravis, rheumatoid arthritis, systemic lupus, pulmonary 
circulation disorders, diabetes with complications, hypothyroidism, liver diseases, peptic ulcers, hepatitis 
B, psychoses, and solid tumors without metastasis).44 Taken together, these data suggest that 
medications used to treat various ocular and systemic disorders may affect ocular surface health. 
 
II.A.2.  Review of Clinical Trials of DED 
 
II.A.2.a.  Questionnaires 
The third major goal of the TFOS DEWS Epidemiology Subcommittee was to review dry eye 
questionnaires.3 To assess developments in this area, a literature review was conducted to identify 
questionnaires used in 1) epidemiologic studies to ascertain cases or study natural history, 2) in 
screening to identify individuals at risk, and 3) in clinical practice to assess treatment effects or disease 
severity. Available data on validation, reproducibility, and responsiveness were assessed. Seven newer 
questionnaires were identified and summarized in Table 4. 
The Ocular Surface Disease Index (OSDI)53 featured prominently among these studies,45, 50 and 
minimal clinically important difference (MCID) values have been assessed for various OSDI categories for 
DED.54 A newer measure, the Ocular Comfort Index (OCI), uses Rasch analysis to produce estimates on a 
linear interval scale; it was shown to positively correlate with the OSDI score (p < 0.0001) and to 
negatively correlate with tear film breakup time (TFBUT [p < 0.0001]), and was able to detect 
improvement in symptoms of dry eye in individuals before and after treatment (p <0.0001).55 The 
Symptom Assessment iN Dry Eye (SANDE) Questionnaire,52 published early 2007, is presently used as an 
instrument in some current clinical trials of DED, and has been found to be equivalent to the OSDI.56 Also 
of note was the 5-Item Dry Eye Questionnaire (DEQ-5),50 in which frequency of watery eyes (r=0.48), 
discomfort (r=0.41), dryness (r=0.35), and late-day intensity of discomfort and dryness (r=0.42, 0.36) all 
significantly correlated to self-assessed severity. The nature of the items varied widely in terms of the 
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parameter being assessed and response options—e.g., visual analogue scale (VAS) and categorical scales. 
In these recent reports, there was emphasis on the nature of dry eye symptoms, including irritation 
symptoms and describing how the eyes feel. Distinct (but equally important) was the domain of vision-
targeted, health-related impact of DED, such as effects on visual function and quality of life (QoL). Further 
refinement is necessary to ensure that surveys are sufficiently sensitive to detect response to treatment. 
 
II.A.2.b.  Clinical trials 
To assess the progress in research and development of dry eye treatments since the 2007 TFOS 
DEWS report, a survey was performed on studies newly registered on ClinicalTrials.gov in 2010.57 Of the 
76 studies identified with the search words “dry” and “eye”, approximately 60 were related to DED 
(unrelated studies were on age-related macular degeneration). Of the DED studies, most were classified 
as interventional studies (Table 5), involving topical, oral, or surgical intervention for patient groups with 
varying degrees of dry eye. Interestingly, of the observational studies that were active in 2010, five were 
sponsored by companies,58-62 and one of these was a natural history study of patients with DED.61 These 
studies might be considered a direct result of the “call to action” of the 2007 TFOS DEWS report. It is also 
interesting to note that there were five registered studies of oral omega fatty acid supplementation for 
dry eye,63-67 multiple tear lubrication (artificial tear) studies, and several pharmaceutical studies in phase 
II and phase III. Collectively, this indicates positive growth in the field and active research and 
development programs in the pharmaceutical companies. 
 
II.A.3.   Summary and Conclusions 
Since 2007, significant advances have been made in the global prevalence assessment of DED. 
Prevalence is approximately 9% based on tests and 22% based on symptoms. Moreover, prevalence is 
upwards of 30% in Asian populations (over 50% in certain demographics). Recent ten-year incidence 
data (21%) and risk factor assessments (e.g., antidepressants, other medications, and systemic 
comorbidities) have refined our existing knowledge base. There has been an overwhelming increase in 
studies on DED, including clinical trials, since 2007—a testament to the impact of TFOS and DEWS. 
However, further research is needed on the natural history of DED. Newer surveys need to be validated to 
ensure that they are able to monitor therapeutic response, and the impact of MGD on survey reporting 
requires further assessment. 
 
II.B.  Surgery-induced DED (José Benitez del Castillo, MD) 
Dry eye is a common complication of ocular surgery, and involves a complex interplay between 
altered corneal innervation and ocular surface tear dynamics. Not only can dry eye affect patient 
satisfaction, but it also may affect surgical outcome. Dr. Benitez del Castillo reviewed the pathophysiology 
of surgery-induced dry eye and discussed strategies for prevention and treatment. 
 
II.B.1.   Corneal Refractive Surgery 
The cornea is the most densely innervated tissue in the body, and refractive procedures are 
known to cause corneal sensitivity impairment. This may lessen reflex-induced lacrimal secretion and 
reduce blink rate—thus promoting evaporative loss and inducing or worsening dry eye.68 Dry eye is a 
common patient complaint after refractive surgery, as well as a common reason why patients initially 
seek refractive surgery. Refractive surgery may cause various problems on the ocular surface; conversely, 
certain ocular surface diseases (including dry eye) may affect refractive surgery results. 
 
II.B.1.a.  Pathophysiology of LASIK-induced dry eye 
Dry eye is the major cause of patient dissatisfaction following laser-assisted in situ keratomileusis 
(LASIK), causing frustration for both patients and surgeons.69, 70 LASIK causes a temporary decrease in 
ocular surface health, and both tear secretion and corneal sensitivity are reduced three months after 
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surgery, with recovery to normal values at six months postsurgically.71 Detailed analysis of mechanical, 
chemical, and thermal sensation using the Belmonte noncontact esthesiometer showed that corneal 
sensitivity did not recover in many cases until 54 months after surgery, and recovery was slower after 
hypermetropic LASIK.72 
Nerve bundles enter the cornea (middle third of the stroma) at the periphery in a radial fashion 
parallel to the corneal surface, and lose their myelin sheaths within 1 mm of the limbus.72 Of the corneal 
nerves, 20% are mechanonociceptors that respond to only mechanical forces; 70% are polymodal 
nociceptors that respond to chemicals, heat, and inflammatory mediators in addition to mechanical 
forces; and 10% are cold thermoreceptors that respond to evaporative cooling.73 It was previously 
believed that most nerves enter the stroma nasally and temporally,74 but subsequent studies have 
suggested that equal numbers of nerves penetrate in all quadrants.75 Indeed, corneal sensation and dry 
eye following LASIK are not affected by position or angle of the corneal flap hinge, which disrupts afferent 
sensory nerve fibers.76 In patients without previous dry eye, rose bengal staining confined to the flap is 
likely due to LASIK-induced neurotrophic epitheliopathy (LINE), as Schirmer’s test is normal; LINE 
resolves 6–8 months after surgery.77 
Corneal nerve alterations have been observed in dry eye of various origins, including Sjögren's 
syndrome and non-Sjögren's etiologies.72, 78 The high prevalence of dry eye symptoms after refractive 
surgery, without dramatic changes in tear secretion, has been suggested to represent neuropathic pain or 
neurotrophic keratopathy (LINE) rather than actual tear film deficiency.79 In neuropathic pain, central 
sensitization becomes an autonomous activity that is independent of the stimulus, and the transition 
from chronic to neuropathic pain does not have a discrete boundary. Evidence of neuropathic pain after 
LASIK includes disparity between signs and symptoms; depressed corneal sensitivity to touch; decreased 
and abnormal corneal nerves on confocal microscopy; unexplained photophobia and blepharospasm; 
exaggerated pain in response to instilled drops, Schirmer´s testing and airflow incident on the eye; and 
persistent burning after pharmacologically induced corneal anesthesia.80 After corneal nerves are cut in 
refractive procedures, the pathophysiology of neuropathy may be due to invading nerve fibers into the 
denervated areas, as well as regenerating axons and developing microneuromas, leading to hyperalgesia. 
In addition to reduced corneal sensation and tear secretion,71 LASIK has been shown to reduce 
tear clearance, with concomitant increases in proinflammatory interleukin-1 concentrations and activity 
of matrix-degrading enzymes MMP-3 and MMP-9 in tear fluid.81 Reductions in goblet cell density may 
also contribute to the pathology of postoperative dry eye. In LASIK, application of the microkeratome 
suction ring has been correlated with reduced goblet cell density and development of dry eye.82, 83 
In summary, in LASIK-induced ocular surface disease, corneal nerve alterations are central to a 
vicious circle of hypo- and hyperstimulation, reduced blink rate, reduced goblet cell density, and tear film 
instability (comprising reduced tear secretion/clearance and meibomian lipids). The resulting 
hyperosmolarity may be compounded by cytokines that may further distort sensory information and 
inhibit mucin production. 
 
II.B.1.b.  Dry eye in other corneal refractive procedures 
In superficial corneal refractive procedures such as photorefractive keratectomy (PRK) and laser-
assisted subepithelial keratomileusis (LASEK), neuronal injury is restricted to the basal epithelial-
subepithelial (sub-Bowman’s) nerve plexus, and transient sensory loss correlates with ablation depth.84 
It has been suggested that higher postoperative levels of nerve growth factor (NGF) may explain the 
milder dry eye symptoms and corneal sensory loss observed after PRK compared to LASIK.85 Small 
incision lenticule extraction (SMILE) also causes fewer alterations to the ocular surface and corneal 
innervation than LASIK; accordingly, preliminary results suggest a decreased DED incidence with this 
procedure.86 Controlled studies, with large samples and objective methods for measuring and quantifying 
subbasal nerve density, are necessary to establish the safety of mitomycin C for preventing postoperative 
corneal haze. 
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II.B.1.c.  Risks and risk factors 
The risk factors for developing LASIK-induced dry eye have been examined,87-89 and reported to 
be increased in women and Asians, and associated with include high refractive defects, ablation depth, 
low preoperative Schirmer’s test, preoperative dry eye, and long duration of contact lens wear. 
Contact lens intolerance due to dry eye is a common reason why patients seek refractive surgery. 
It has been estimated that more than 75% of patients seeking LASIK have symptoms of dry eye, and while 
preexisting dry eye does not appear to affect LASIK efficacy, it does predispose patients to severe 
postoperative dry eye.90 
Post-LASIK dry eye may affect refractive results. Increased rates of refractive regression have 
been observed in patients who developed dry eye after LASIK for hyperopia91 and myopia.92 Although it 
is not clear whether there is a causal association between dry eye and refractive regression, proposed 
pathological mechanisms include epithelial hyperplasia, altered growth factors, and abnormal 
remodeling.92 
 
II.B.1.d.  Prevention and treatment 
In order to optimize results and minimize dry eye following refractive procedures, several tests 
and precautions should be taken preceding and following surgery. 
A pre-LASIK ocular surface study is recommended, which includes asking the patient about 
existing dry eye symptoms (including contact lens intolerance). Preferred screening and diagnostic tests 
for dry eye have been previously reviewed by the 2007 TFOS DEWS Diagnostic Methodology 
Subcommittee,2 and include TFBUT, Schirmer’s test, slit lamp examination (particularly of Meibomian 
gland orifices), fluorescein and lissamine green staining, and osmolarity. 
Preoperative treatment should aim to achieve the best ocular surface for as long as possible before 
surgery. Patients should avoid contact lens wear and maintain good lid hygiene. Recommendations for 
dry eye management, based on disease severity and patient profiles, have been summarized by the 2007 
TFOS DEWS Management and Therapy Subcommittee,4 and preoperative treatment may include artificial 
tears, steroids, punctal/canalicular plugs, oral tetracycline, 0.05% cyclosporine, and omega 3 fatty acid 
supplementation. Physicians may also wait six months before excluding patients as LASIK candidates, 
and if there are no symptoms and examination is normal, offer surgery and continue treatment for at 
least six months after surgery. 
Intraoperative treatment should minimize the use of topical anesthetic. Lubrication should be 
achieved with substances of low coefficient of friction (e.g., hyaluronate, carboxymethylcellulose 1%, 
carbomers) rather than high coefficient of friction (balanced salt solution, polyvinylalcohol, 
carboxymethylcellulose 0.5%, and hydroxypropylmethylcellulose). 
Postoperatively, the patient should keep the eyes closed as long as possible during the early hours. 
Postoperative treatment may be similar to preoperative treatment, and include artificial tears, steroids, 
punctal/canalicular plugs, oral tetracycline, 0.05% cyclosporine, and omega 3 fatty acid supplementation. 
Other treatments may include autologous serum, and platelet-rich plasma. 
Neuropathic pain after refractive surgery may be treated with autologous serum (with or without 
lidocaine drops, in doses ranging from 0.01% to 0.1%); pregabalin (Lyrica®), a common treatment for 
peripheral neuropathic pain, in doses starting at 150 mg/day and increasing to a maximum of 600 
mg/day; duloxetine (Cymbalta®), a common treatment for diabetic neuropathy, starting at 30 mg/day 
and increasing to 120 mg/day, with evaluation at 2 months; and therapeutic contact lenses such as the 
BostonSight® PROSE (prosthetic replacement of the ocular surface ecosystem). 
 
II.B.2.   Cataract Surgery 
Cataract surgery may also alter corneal sensitivity and ocular surface dynamics. Deteriorated 
corneal sensitivity and tear physiology have been observed immediately following phacoemulsification, 
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with recovery times of approximately one month for tear function and three months for corneal 
sensitivity.93 The incidence of dry eye after phacoemulsification has been reported to approach 10%.94 
 
II.B.2.a. Pathophysiology 
The pathophysiology of dry eye induced by cataract surgery involves altered tear turnover. A 
standardized protocol has been developed for measuring basal tear turnover based on the decay of 
fluorescein concentration in tears,95 and in normal subjects, mean tear turnover rate is 17.5%/min +/- 
3.4, and declined approximately 0.15%/min for each additional year of age. In patients experiencing dry 
eye after cataract surgery, investigations have found a reduction in lacrimal flow, decreased TFBUT and 
Schirmer values, and squamous metaplasia in the lower lid-covered conjunctiva.96 Alterations in eyelid 
anatomy and function have also been reported after phacoemulsification. Ptosis has also been reported in 
patients following phacoemulsification (<1mm ptosis in 30% of patients and 1-2.5mmin 8%), along with 
altered margin reflex distances, decreasing tear clearance.97 
 
II.B.2.b. Risks and risk factors 
The risk factors for dry eye induced by cataract surgery are unclear, but may involve speculum 
time and type (e.g., aspirating vs. nonaspirating speculum).98 Retrobulbar anesthesia may also be 
associated with an increased frequency of ptosis. Other risk factors of dry eye following cataract surgery 
include contact lens intolerance. 
Dry eye has also been associated with increased risk of visual complications following cataract 
surgery. Retinal image quality is reported to be decreased in patients with dry eye following 
phacoemulsification.94 Following multifocal intraocular lens implantation, dry eye has been reported to 
cause 15% of patient complaints of blurred vision and 5% of photic phenomena.99 
 
II.B.2.c.  Prevention and treatment 
Preoperative treatment should aim to protect and improve the ocular surface. Antibiotics and 
toxic preservatives should be avoided. Additionally, preoperative surveys and tests will aid in selecting 
good surgical candidates in order to reduce the risk of dry eye following cataract surgery. Risk factors 
include contact lens intolerance. Good surgical candidates have high TFBUT (>8 seconds), whereas poor 
candidates have low values (<4 seconds). High tear volume (Schirmer test >10 mm) is also favorable, 
because if there is no reflex tear production, the patient is not a good candidate. Ocular surface stress 
tests may uncover underlying pathologies that may inform treatment; if significant keratitis is observed 
after the application of diagnostic drops in the clinic, this indicates that special therapies may be 
necessary in the perioperative period. Finally, patients should be alerted to the risks in the informed 
consent. 
Intraoperative treatment should similarly aim to preserve the ocular surface. Anesthetics and 
other substances used on the ocular surface should be low toxicity, and speculum time should be 
minimized to reduce associated trauma. Intrasurgical desiccation should be avoided, and incisions should 
be as small as possible. 
Postoperative treatment should aim to avoid further damage to an already-unstable ocular 
surface. Antibiotic use should be minimized. After cataract surgery, the addition of preservative-free 
artificial tears containing hydroxypropyl (HP)-Guar to standard treatment has been found to reduce 
ocular surface inflammation and dry eye compared to standard treatment alone (tobramycin and 
dexamethasone eye drops);100 thus, preservative-free artificial tears may be an important postsurgical 
consideration. 
 
II.B.3.   Glaucoma Surgery 
Glaucoma surgery represents a different scenario than refractive or cataract surgery. Patients 
typically have lower expectations and are more accepting of ocular surface discomfort, since eye 
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irritation may arise in response to glaucoma medical treatment. Some glaucoma medications have an 
adverse effect on the ocular surface, so DED epitheliopathy, subconjunctival fibrosis, and dry eye-like 
symptoms may be present perioperatively in some patients. 
A study comparing the long-term results of filtering surgery using either a limbal-based or fornix-
based flap found differences in relation to dry eye symptoms (sicca score).101 However, if mitomycin C is 
used, dendritiform inflammatory cells increase in blebs, and the transcellular pathway of the aqueous 
humor, which has been proposed to involve ocular surface goblet cells, is decreased.102 
An injured ocular surface appears to decrease success of glaucoma surgery. Lower expression of 
human leucocyte antigen-DR (a marker of conjunctival inflammation) and higher expression of trefoil 
factor family 1 and MUC5AC are observed in successful glaucoma surgeries, suggesting less injury and 
improved healing of the ocular surface in successful surgeries compared to failures.103 It is likely that 
long-term use of topical glaucoma medications may have adverse effects on the ocular surface (and thus 
on surgical outcomes); however, pressure control is understandably a high priority for glaucoma patients 
and surgeons. 
 
II.B.4.   Summary and Conclusions 
Many patients seeking ocular surgery have preexisting dry eye, and surgery may worsen or induce 
dry eye and alter the ocular surface, thus affecting the patient´s satisfaction. Moreover, ocular surface 
injury may affect surgical results. Therefore, the ocular surface should be examined preoperatively, 
because damage is higher if the ocular surface is already abnormal. Careful patient selection and 
education, combined with preoperative, intraoperative, and postoperative treatment, will improve 
refractive results and patient satisfaction. The routine addition of tear substitutes to postoperative 
treatment may improve results and patient satisfaction. With the aging baby-boomer population, cataract 
surgery will continue to be a commonly experienced medical procedure. The overlap of DED in this 
population, and the clinical indication that optimizing the ocular surface prior to cataract surgery results 
in improved outcomes, warrant future research and indicate unmet needs. 
 
II.C.  Contact Lens-associated DED (Mark Willcox, PhD) 
The 2013 report of the TFOS International Workshop on Contact Lens Discomfort (TFOS CLDW) 
provided a critical assessment of the field of contact lens discomfort, and laid the groundwork for further 
investigation and clinical development.104 In the current meeting, Dr. Willcox summarized the previous 
findings of the TFOS International Workshop on Contact Lens Discomfort and reviewed recent 
advancements. 
 
II.C.1.  Epidemiology of Contact Lens Discomfort 
The Subcommittee on Epidemiology of the TFOS CLDW found the frequency of contact lens 
discomfort to be approximately 50% (reported range of ~30% to ~80%), with variations attributed to 
the populations evaluated, questionnaires used, symptoms evaluated, contact lens types, and care 
solutions.105 
Recent studies have identified significant associations between contact lens wear and dry eye. In 
Singapore, the prevalence of symptomatic DED (12.3%) had a significant association with contact lens 
wear (OR 2.96, 95% CI: 1.81-4.83).37 In the Beaver Dam Offspring Study (BOSS), dry eye prevalence 
(14.5%) was also significantly associated with contact lens wear (2.01; 95% CI, 1.53-2.64).33 
 
II.C.2.   Definition and Classification of Contact Lens Discomfort 
The TFOS CLDW report of the Definition and Classification Subcommittee defined contact lens 
discomfort as “a condition characterized by episodic or persistent adverse ocular sensations related to 
lens wear, either with or without visual disturbance, resulting from reduced compatibility between the 
contact lens and the ocular environment, which can lead to decreased wearing time and discontinuation 
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of contact lens wear.”106 Indeed, discomfort is the leading reason for contact lens dropout, accounting for 
approximately 50% of discontinuations in an international web-based survey.107 
The Definition and Classification Subcommittee categorized contact lens discomfort into two 
major subclasses, which were further subdivided based on potential contributing factors (Figure 1). This 
classification scheme provides a framework for assessing the etiology and pathophysiology of contact 
lens discomfort, discussed below. 
 
II.C.3  Etiology and pathophysiology 
Based on the previously described classification scheme (Figure 1), the etiology and 
pathophysiology of contact lens discomfort are interrelated with the characteristics of contact lenses 
(including materials, design, fit and wear, and lens care systems) or the contact lens environment. The 
latter includes the ocular environment (structures of the eye and adnexa, tear film, and associated 
glands), patient factors (inherent or modifiable), and the external environment. 
 
II.C.3.a.  Contact lenses and lens care products 
Contact lens characteristics that may contribute to discomfort have been reviewed in detail in the 
TFOS CLDW report of the Contact Lens Materials, Design, and Care Subcommittee.108 These included 
water content, surface friction, lens fit, tear film deposits, time of day, and lens care products. Among the 
attributes of contact lens materials, friction was the sole factor that appeared to be associated with 
comfort. It was also unclear whether care solutions were associated with comfort levels, although 
wearing lenses on a daily disposable basis has been reported to increase the comfort of lenses when 
compared to using them on a daily wear basis with care solutions. Other factors affecting contact lens 
comfort were associated with design (e.g., size, shape, and contour of lens edges). 
A recent study found almost no correlation between contact lens-associated dry eye with 
compliance factors related to aspects of lens care (replacement of lenses, lens cases, and solutions) or 
wear (e.g., sleeping with lenses), even despite overall low compliance.109 Another recent study found no 
relation between contact lens replacement during the day and discomfort.110 These findings highlight the 
need for further research on etiological factors other than compliance or lens replacement, including 
stimulation of ocular surface tissues or nociceptors by the contact lens. 
 
II.C.3.b.  Contact lens interactions with the ocular surface and adnexa 
The TFOS CLDW report of the Contact Lens Interactions with the Ocular Surface & Adnexa 
Subcommittee examined the impact of contact lenses on the ocular surface, with an emphasis on contact 
lens discomfort.111 There was insufficient evidence to support a relation between contact lens discomfort 
with limbal vessel engorgement (redness), limbal stem cell deficiency, and corneal staining. However, 
there was some evidence of more frequent contact lens discomfort in patients with bulbar conjunctival 
staining, and lid wiper epitheliopathy (LWE) appeared to be the most likely cause of discomfort. Lid 
parallel conjunctival folds also had a positive correlation with dry eye in contact lens wearers, with 
possible similar mechanical and friction-related etiologies as LWE. Palpebral roughness and lid 
sensitivity were also found to have a possible correlations discomfort. CL wear may have a causative 
association with meibomian gland dysfunction (MGD). 
Recent studies have examined a possible link between Demodex infestation (eyelash mites) and 
dry eye, but while contact lens wearers were found to harbor higher numbers of Demodex than non-
wearers, there was no association with either dry eye or contact lens discomfort.112, 113 
 
II.C.3.c.  Contact lens interactions with the tear film 
The TFOS CLDW report of the Contact Lens Interactions with the Tear Film Subcommittee 
determined that contact lens discomfort was associated with several tear variables, including lipid layer 
integrity and spread, tear film stability, evaporation, and tear volume.114 
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  A major hurdle identified by the Subcommittee, with regard to drawing conclusions about 
biochemical changes in the tear film, has been the inconsistency in tear collection methods used, which 
has resulted in differences in the tear types collected.114 For example, more invasive techniques induce 
more reflex tearing than less invasive methods. Nonetheless, the Subcommittee found that the most likely 
lipidomic tear film changes are to the polar lipid component, where reduced phospholipid levels possibly 
due to increased secretory phospholipase 2 (sPLA2) activity likely contributes to contact lens discomfort, 
possibly through an effect on tear film lipid layer integrity. The available literature failed to demonstrate 
consistent changes in the tear proteome with contact lens wear, with the possible exception of increased 
lipocalin-1 in contact lens intolerance. Cytokine levels may also be increased with contact lens wear, but 
variations in collection method have resulted in a wide range of cytokine levels being reported in 
different studies, confounding the results, and it was not known whether cytokine levels were associated 
with contact lens discomfort. There also appeared to be an inconclusive relationship between contact 
lens intolerance and mucins, though there was a possible relation with the pattern of mucin degradation. 
A recent study examined cytokine changes in tears and their relationship to ocular discomfort 
with or without contact lens wear.115 Ninety participants were divided into two groups (with or without 
contact lenses) and asked to rate ocular comfort and collect their tears (morning and night) for 10 days. 
Of the cytokines examined, vascular endothelial growth factor (VEGF), best known for its role in 
angiogenesis, was the only factor that positively associated with greater ocular discomfort; however, this 
was not affected by contact lens wear. 
 
II.C.4.   Management and Therapy of Contact Lens Discomfort 
The aim of the Management and Therapy Subcommittee of the TFOS CLDW was to develop an 
evidence-based regime to alleviate contact lens discomfort.116 As data were often equivocal, evidence was 
categorized based on objective criteria (Table 6) adapted from the American Academy of Ophthalmology 
Practice Guidelines and were used in previous TFOS reports.1 The approaches that were assessed (with 
corresponding level of available evidence) are summarized in Table 7. 
 
II.C.4.a.  Management strategies related to contact lenses and care systems 
According to the TFOS CLDW report of the Subcommittee on Management and Therapy,116 
evidence supports adjusting contact lens replacement frequency by using daily disposables, and the 
mechanism may be elimination of the care system. Changing the care system—namely, removing multi-
purpose disinfecting solution (MPDS), appears to be supported by evidence. Wetting agents (packaging 
solution additives or pre-conditioning treatments) have short-term benefits evident early in the wearing 
cycle. 
Mildly favorable evidence supports changing lens material, though additional well-designed 
studies were called for. Altering lens design was supported by varying levels of evidence (depending on 
the particular attribute); however, a practical issue with this approach is the difficulty in manipulating 
individual parameters due to design component interdependence, and unless lenses are custom made, 
control may lie with manufacturer. 
 
II.C.4.b. Management strategies related to contact lens environment 
Tear supplementation (eye drops and wetting agents) were widely regarded as mainstay of 
treatment, and clinical benefit is generally evident in trials (with more-recent studies tending to favor 
complex solutions over saline alone).116 Data have since emerged that degraded lipids and a wax esters in 
the tear film may be associated with a lower non-invasive surface drying time (NISDT), suggesting that 
lipid supplements may alleviate contact lens discomfort by increasing NISDT.117 
In the TFOS CLDW report,116 there was generally little evidence supporting topical medications, 
with only one relevant study supporting the use of azithromycin.118 Two studies on cyclosporine 
produced conflicting results,119, 120 and potential risks do not justify the use of steroids or anesthetics 
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(especially long-term). Data existed on non-steroidal 0.1% diclofenac for reducing post-fitting adaptation 
time for rigid gas-permeable lenses.121 
The TFOS CLDW report of the Subcommittee on Management and Therapy found support for 
dietary supplementation with omega-6 fatty acids (evening primrose oil), but evidence was lacking for 
hydration and omega-3 fatty acid supplementation.116 However, recent data on omega-3 fatty acid 
supplementation showed improved symptom scores and increased TFBUT compared to placebo (corn 
oil).122 
Concerning punctal occlusion, the balance of evidence suggested that increased tear volume is 
beneficial, and that silicone plugs are superior to dissolvable collagen, and that both upper and lower 
occlusion was better than lower lid alone.116 
 
II.C.4.c.  Summary of management strategies for contact lens related discomfort 
The management strategies for contact lens related discomfort may be summarized as follows: 1) 
determine the most likely cause, 2) identify corresponding treatment strategy, and 3) stepwise (additive) 
application of treatments to achieve maximum effect. 
 
II.C.5.  Summary and Conclusions 
The 2013 report of the TFOS CLDW formed the basis for further investigation and clinical 
development.104 Significant momentum is evident in several studies that have since been published, 
which will inform further investigations on contact lens-associated discomfort and DED. Optimized vision 
and comfort through the use of contact lenses, including specialty lenses such as multifocal and toric 
lenses, is an unachieved preference of eye care clinicians. The reasons for this discrepancy, in the 
presence of improved technology, indicate a lack of understanding of the mechanisms of contact lens 
discomfort and a significant unmet need. There is a clear need for best practice design of clinical trials to 
be implemented, such as including appropriate controls so that bias can be reduced. Also, studies 
designed to change one aspect of the contact lens (such as lens edge) whilst maintaining control over 
other aspects (such as size, shape, polymer type and stiffness) should be conducted to isolate specific 
aspects that may relate to CLD. Longitudinal clinical tests and trials should be conducted that may assess 
both short-term and long-term aspects of CLD. Tear film studies that examine lipidomic changes using the 
latest mass spectrometry techniques are required to assess the contribution, if any, of specific lipids to 
CLD. Also, further studies are needed to validate the improvement in CLD in the daily disposable modality 
compared with daily wear to better understand the contribution of the disinfecting solution to CLD.  
 
III. CLINICAL CHALLENGES OF DED 
 
III.A.  Pathophysiology of DED (Anthony Bron, FRCOphth, FMedSci) 
The 2007 TFOS DEWS Report comprehensively assessed the available literature on the 
pathogenesis and natural history of DED, and provided a framework for further investigation.1 Dr. Bron 
summarized significant multidisciplinary developments since the publication of the DEWS Report and 
synthesized the current understanding of the pathophysiology of DED. 
 
III.A.1.  Tear Physiology 
 
III.A.1.a. Tear film composition 
The human tear film has been described in detail in the 2011 report of the TFOS International 
Workshop on Meibomian Gland Dysfunction (MGDW),123 and comprises multiple layers that overlie the 
ocular surface, as well as many tear components that maintain ocular surface health (Figure 2). 
The lacrimal gland produces the aqueous layer (the largest proportion of the tear film) and 
various growth factors therein, including epidermal growth factor (EGF), hepatocyte growth factor 
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(HGF), nerve growth factor (NGF), and retinol.124-126 The lacrimal gland also releases the defense 
proteins, lysozyme, lactoferrin and lung surfactant protein D.126 Plasma cells within the gland produce 
IgA, which is delivered into the tears as secretory IgA (sIgA). 
The ocular surface epithelia express glycocalyx mucins, which ensure the wettability of the 
epithelium.127, 128 Transmembrane mucins, expressed by the corneal epithelium (MUC1, MUC4, and 
MUC16) or the conjunctival epithelium (MUC1, MUC2, and MUC 4), are major components of the 
glycocalyx, reinforced by the presence of galectin-3. Conjunctival goblet cells secrete MUC5AC into the 
tears,128 and the functions of this gel-forming mucin include lubrication, surface tension lowering, 
antimicrobial actions, and scavenging of reactive oxygen species (ROS). Lubricin (proteoglycan-4), a 
boundary surface lubricant that is also produced by ocular surface epithelia, serves to decrease shear 
stress generated during blinking and eye movements.7 
The meibomian glands are the primary source of tear film lipids, which retard evaporation by 8–
10%.129, 130 The tear film lipid layer (TFLL), described in the 2011 report of the TFOS MGDW 
Subcommittee on Tear Film Lipids and Lipid-Protein Interactions in Health and Disease,131 is a highly 
stable film consisting of 3–8 monolayers (Figure 2). The outer non-polar layer is composed of wax and 
sterol esters, and triglycerides,132 whereas the deep polar layer is mainly (O-acyl)-omega-hydroxy fatty 
acids (OAHFAs) and phospholipids, though the exact composition is controversial.133 These polar lipids, 
interfacing with the aqueous phase of the film, facilitate the rapid spread of the lipid film over the ocular 
surface with each blink. The viscoelastic tear film stabilizes within 1-2 seconds of the blink, ensuring the 
low turnover of the TFLL (approximately 10% of the turnover rate of the aqueous layer).134 Lipocalin, a 
lacrimal lipid-binding protein, likely stabilizes this interface. Alterations in the physical properties of 
meibomian lipids may disrupt the structure of the TFLL, as seen in MGD,135 discussed later. 
 
III.A.1.b.  The lacrimal functional unit 
The ocular surface, lacrimal system, meibomian glands, and neural interconnections are 
components of the lacrimal functional unit.136 This integrated unit, which maintains ocular surface 
homeostasis and is central to the pathophysiology of aqueous-deficient dry eye,137 was discussed in detail 
the 2007 report of the TFOS DEWS Definition and Classification Subcommittee68 and reviewed by the 
TFOS CLDW Report.111 Sensory impulses from the ocular surface regulate secretions (lacrimal, 
conjunctival, and possibly Meibomian). Blink action is supported by central nervous, sympathetic, 
endocrine, and immunological influences. his unit promotes tear film stability, corneal transparency, 
and accurate retinal image formation. 
 
III.A.1.c.  The tear meniscus 
In the interblink, the tears reside in three compartments: the fornical sac, the tear menisci and the 
tear film. The tear menisci form as a result of surface tension and separate from the tear film immediately 
after the blink. In the presence of fluorescein, this separation is seen as a black line (Figure 3).138 Fornical 
tears drain into the menisci and then into the nasolacrimal duct; importantly, tears are also lost by 
evaporation. Because meniscus volume reflects both total tear volume and lacrimal secretion rate, 
meniscus parameters (such as radius and curvature) are used in the diagnosis of DED. 
 
III.A.2.  Central Mechanisms of DED 
The pathological mechanisms of DED may have different etiologies, depending on the disease 
subtype,126 but their central mechanisms converge and are interrelated. This is reflected in the definition 
of DED and its classification. The key features of dry eye were outlined in the 2007 report of the TFOS 
DEWS Definition and Classification Subcommittee as hyperosmolarity and inflammation at the ocular 
surface.68 Other mechanisms, occurring in parallel, may contribute to dry eye and complicate the disease 
state. 
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III.A.2.a.  Hyperosmolarity 
Tear osmolarity relates to plasma osmolarity and is modulated by evaporation and tightly 
regulated by blink rate and tear secretion.126 Thus, the lacrimal functional unit is central to the 
homeostasis of tear osmolarity. Tear hyperosmolarity may result from reduced aqueous tear flow (a 
consequence of lacrimal failure) and/or increased evaporation from the tear film. Environmental 
conditions that favor evaporative loss include low humidity and high airflow; physiological conditions 
include MGD and resulting instability of the TFLL. 
As illustrated in Figure 4, tear film instability and tear hyperosmolarity drive the core mechanisms 
of dry eye.139 Importantly, this implies hyperosmolarity of the exposed ocular surface cells, with aqueous-
deficient dry eye (ADDE) and evaporative dry eye (EDE) as the major disease forms. This definition is a 
practical convenience; since evaporation is the basis of hyperosmolarity in both forms; lid closure or 
prevention of evaporation in theory should reverse all those features of DED due to tear hyperosmolarity. 
However, while it is a core mechanism, hyperosmolarity does not preclude etiological factors such as 
preservative toxicity, or direct inflammatory attack of the ocular surface in Sjögren’s syndrome, from 
inducing ocular surface damage, leading to tear film breakup and exacerbating tear hyperosmolarity. 
Baudouin and colleagues have stressed that tear hyperosmolarity leads to a “vicious circle” of 
inflammatory events so that the disease becomes self-perpetuating.140 The resulting autonomous state 
might not respond to efforts to prevent evaporation, and might require other measures to reverse. 
Recent evidence suggests that spatial and temporal variations in tear osmolarity may affect tear 
film stability, and the magnitude of these variations may in turn vary between normal and symptomatic 
eyes. Local increases in evaporation, resulting from prolonged interblinks or environmental factors (such 
as relative humidity and wind speed), drive tear film breakup, and massive increases in osmolarity are 
predicted at the center of tear film ruptures.135 Spots of ocular surface cooling, assessed by infrared 
thermography, colocalize with tear film breakup assessed by fluorescein instillation, and reflect local 
increases in evaporation.141 Mathematical modeling of the mass and solute balance of the tears, suggests 
that, in healthy eyes, osmolarity is higher in the tear film than in the menisci, but that the differential is 
much greater in DED.142 Higher tear osmolarity and greater variation over time are also observed in 
patients with dry eye symptoms compared to normal subjects.143 Inter-eye variation in tear osmolarity, 
which was demonstrated earlier to be greater in DED,144 has recently been found to correlate 
significantly with increasing disease severity.145 
 
III.A.2.b.  Inflammation 
As outlined in the 2007 report of the TFOS DEWS Definition and Classification Subcommittee,68 
damage to the ocular surface epithelium, driven by tear hyperosmolarity and other etiological factors, 
activates an inflammatory cascade at the ocular surface, which in turn releases inflammatory mediators 
into the tears. Epithelial damage can also affect the goblet cells and the epithelial cells that produce 
glycocalyx mucin, causing tear film instability and further exacerbating hyperosmolarity. Various 
etiologies, including xerophthalmia, ocular allergy, topical preservatives, and contact lens wear, may also 
trigger tear film instability independently of tear hyperosmolarity. 
In recent years, there has increasing evidence that ocular surface stress leads to infiltration by 
autoreactive T-cells. Experimental models of desiccating stress have demonstrated that infiltrating 
autoreactive T-cells are involved in the immunopathogenesis of murine DED.146-150 In brief, desiccating 
stress alters epithelial cytokine expression (e.g., inducing IL-1, TNFα and IL-6) to favor maturation of 
antigen-presenting cells. These migrate to the regional lymph nodes, where they engage with naïve T 
lymphocytes to stimulate a T helper (Th) cell response. Meanwhile, at the ocular surface, IFNγ not only 
induces apoptosis and squamous metaplasia of ocular surface epithelia, but also upregulates chemokines 
and adhesion molecules (CAMs) such as ICAM-1. IFNγ and ICAM-1 may also underlie the induction of the 
cornified envelope proteins responsible for squamous metaplasia.151 
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Recent studies have examined the correlation between inflammatory mediators and parameters of 
the tear film and ocular surface, yielding insight into the diagnostic potential of cytokine and chemokine 
profiles. Yoon et al.152 observed increased expression of IFNγ-inducible chemokines CXCL9, 10, 11, and 
CXCR3 in the tear film and ocular surface of patients with DED, particularly in patients with Sjögren’s 
syndrome vs. non-Sjögren’s dry eye. CXCL11 levels, in particular, correlated significantly with parameters 
such as low basal Schirmer values, low tear clearance, kerato-epitheliopathy, and reduced goblet cell 
density. Lam et al. examined cytokine profiles in dysfunctional tear syndrome using a Luminex bead 
assay,153 and found that many of the cytokines that are elevated in dry eye are also markers for ocular 
surface inflammation in seasonal allergic conjunctivitis (SAC), vernal keratoconjunctivitis (VKC), and 
atopic keratoconjunctivitis (AKC). Increases in interleukins (IL 1α, 1β, 6, 8), IFNα, and MIP-1α correlated 
with DEWS severity grade, and EGF levels correlated positively with Schirmer values and inversely with 
corneal staining. IL-6 showed the greatest correlation with clinical severity (signs and symptoms). 
Moreover, the ratio between IFNγ (marker for Th-1 inflammation) and IL-13 (marker for Th-2 
inflammation) was increased in dry eye, correlating with goblet cell loss and metaplasia in a dry eye 
model. 
 
III.A.2.c.  Symptoms 
The central mechanisms of DED are important causative factors in symptomology. Tear 
hyperosmolarity, which may be diffuse,154 or focal when accompanying tear break up,135 is a potent 
source of irritation and pain. Reduced lubrication,155 due to loss of mucin gel and glycocalyx (and fluid in 
ADDE), is another. This may be compounded by lid wiper epitheliopathy,156 or by parallel conjunctival 
folds (LIPCOF).157 Inflammatory mediators may stimulate nociceptors directly or lower the threshold of 
pain-sensitive neurons, resulting in hyperesthesia.158 Sensory nerve damage also may lead to chronic, 
neuropathic firing.159 While the highest density of sensory innervation is at the center of the cornea (over 
10 times that of dental nerve pulp), the posterior lid margin mucosa has similar sensitivity, and could be 
an important source of symptoms.160, 161 However, it is unclear what happens to lid margin sensitivity 
through the course of any form of DED. 
Dry eye symptoms may not only derive from multiple sources, but may also change during the 
evolution of the disease. For example, it is possible that inflammatory events release algesic mediators to 
cause early symptoms. Corneal hypersensitivity may occur both in early and advanced disease. 
Alterations in the surface glycocalyx, a loss of surface wettability, and loss of goblet cell mucin may result 
from inflammation; combined with insufficient aqueous volume, these events are potential contributors 
to shear-related symptoms. Current tests of pathology may be insufficient to delineate the spatio-
temporal complexity of these events, which may explain why correlations between signs and symptoms 
are so poor or variable. In the clinical management of DED, an unmet need is the development of 
biomarkers that correlate with symptoms, which may provide more successful correlations of signs and 
symptoms in the future. On the other hand, biomarkers that do not correlate may instead characterize 
other features of the disease, such as inflammation and may confirm intrinsic mechanisms. 
 
III.A.3.  Some Etiologies and Mechanisms of DED 
III.A.3.a.  Meibomian Gland Dysfunction 
The anatomy, physiology, and pathophysiology of the meibomian gland were discussed in detail in 
the 2011 TFOS MGDW report.162 Briefly, secretion from meibomian gland occurs under the constant force 
of multiple holocrine secretory acini, and contraction (during lid movement) of Riolan’s muscle drives the 
delivery of meibomian oil onto the lid margin and tear film. In MGD, quantitative reduction of, and 
chemical changes in, meibum lipids and proteins occur; moreover, there is a loss of the polar lipid, 
OAHFA, which is critical for the interaction of the TFLL with the aqueous subphase.131 Thus, the TFLL 
loses its structure, becoming more heterogeneous, and thinner. Spreading of the TFLL and subsequent 
stabilization are both impaired. This is accompanied by increased permeability, and the aforementioned 
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hotspots of evaporation and hyperosmolarity.135 Noninvasive meibography has shown that meibomian 
gland loss increases with age.163 Tear film interferometry has demonstrated vertical patterns in the TFLL 
in MGD, in contrast with horizontal in normal patients.164 
According to the TFOS MGDW Definition and Classification Subcommittee, MGD is classified into 
two major categories based secretion: low-delivery and high-delivery states, the latter being less well 
characterized. Low-delivery MGD is further classified as hyposecretory, or obstructive. In the non-
cicatricial form of obstructive MGD (see below), the key pathological event is occlusion of terminal duct 
due to hyperkeratinization, leading to progressive ductal dilatation and acinar atrophy. Whether 
inflammatory events lead to hyperkeratinization is speculative at the moment. We have proposed that 
Marx’s line may provide a route by which inflammatory mediators gain access to the terminal duct and 
stimulate the production of cornified envelope proteins that are a part of the keratinization process.138 A 
similar mechanism may explain the forward movement of Marx’s line and the mucocutaneous junction 
with age and its relation to MGD.165 
Obstructive MGD is further subcategorized as cicatricial or noncicatricial.166 In noncicatricial 
MGD, meibomian orifices are in their normal anatomic positions, anterior to the mucocutaneous junction 
(MCJ) and Marx’s line, whereas in cicatricial MGD the ducts and orifices are dragged posteriorly across 
the MCJ into the mucosa of the lid margin and tarsal plate. Occlusion occurs by a cicatricial process. This 
form may occur in conjunction with the non-cicatricial form but is particularly associated with scarring 
conjunctival disease, such as mucous membrane pemphigoid, Stevens-Johnson syndrome, and trachoma. 
While it remains unclear whether inflammation in non-cicatricial MGD is a cause or a result of 
meibomian gland obstruction, IFNγ, as mentioned earlier, may underlie the induction of the cornified 
envelope proteins responsible for squamous metaplasia, contributes to terminal duct obstruction in 
MGD.151 The cornified proteins calgranulin A and B (also termed S100A8 and S100A9, and together 
calprotectin), which have roles in innate immunity, barrier functions, and stress signaling, have been 
shown in proteomic studies to correlate with MGD severity signs or redness, and visual blur.167 These 
tear film proteins may originate, at least in part, from the meibomian gland, given that their gene 
expression is significantly increased in this tissue in human MGD.168 
 
III.A.3.b.  Reflex block 
As discussed by the 2007 report of the TFOS DEWS Definition and Classification Subcommittee,68 
epithelial injury in DED stimulates corneal nerve endings, leading to discomfort, increased blinking and 
compensatory reflex lacrimal tearing. It has been suggested that a high reflex input underlies neurogenic 
inflammation within the gland, which not only causes tissue damage but also a reflex secretory block. A 
receptor block may be also caused by circulating antibodies to the M3 receptor. Chronic surface damage 
results in reductions in corneal sensitivity and reflex tear secretion. The loss of sensory reflex drive from 
the ocular surface to the lacrimal gland may reduce tear delivery. Reflex secretory block may also 
underlie the pathology of eye disease caused by ocular surgery, contact lens wear and certainly occurs 
with the chronic use of topical anesthetics. Indeed, Jordan and Baum showed in 1980 that bilateral topical 
anesthesia (i.e., total loss of ocular sensory drive) reduces tear secretion.169 However, bilateral topical 
anesthesia causes a reduction in blink rate,170 similar to the significant fall in blink rate following 
refractive surgery, which may persist for several months after surgery.90 It is likely that trigeminal inputs 
feed centrally to reflex centers that regulate lacrimal secretion and blinking, and to cognitive centers that 
mediate pain and other sensory modalities. 
 
III.A.3.c.  Lacrimal inflammation 
DED, from various etiologies, is conveniently classified according to whether there is insufficient 
lacrimal secretion (ADDE) or excessive evaporative loss (EDE). However, despite this established 
nomenclature, both forms of DED have a component of evaporative loss; i.e., almost all dry eye is 
evaporative, with MGD as the archetypal cause. DED also may involve a combination of ADDE and EDE,43 
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as illustrated in Figure 5. Indeed, in a 2011 multicenter study of 299 subjects in USA and Europe, 145 224 
were designated as having DED; and using a cut-off of < 7 mm Schirmer for ADDE and an MGD score cut-
off of >5, 79 subjects were considered pure MGD-EDE, 23 pure ADDE, and 57 to have a combination of 
MGD with ADDE. The ratio of pure EDE to pure ADDE was found to be 3:1, and could have been as high as 
7:1 if the Schirmer cut-off was reduced to 5 mm or lower. 
Feedback events via the lacrimal functional unit raise the possibility that in advanced DED, organic 
dry eye states may be modified by an added functional component (Figure 5). Thus it is suggested that in 
aqueous-deficient dry eye, defective spreading of the TFLL adds an evaporative (EDE) component to the 
ADDE. In EDE on the other hand, it is proposed that ocular surface damage caused by tear 
hyperosmolarity blocks the compensatory reflex sensory drive to the lacrimal gland, thereby adding an 
aqueous-deficient component. In this way, hybrid dry eye states could occur.43 
Lacrimal gland inflammation, involving infiltration of T-cells followed by B-cells and plasma 
cells,171 could compound meibomian terminal duct obstruction. Inflammatory products of the lacrimal 
gland or lid margin could modify the surface phenotype and induce cornified envelope proteins 
responsible for squamous metaplasia, contributing to terminal duct obstruction.151 This is supported by 
the proteomic correlation of calgranulin A and B with MGD severity.167 Thus, it is possible that 
inflammation is a key mechanism of keratinization process, via production of cornified envelope 
proteins.138 
Inflammatory lacrimal damage is a key pathological mechanism in systemic autoimmune 
disorders such as Sjögren syndrome, as well as in non-Sjögren syndrome dry eye (NSSDE). In Sjögren 
syndrome, described by the TFOS DEWS Definition and Classification Subcommittee,68 the immune 
system targets the lacrimal and salivary glands, giving rise to dry eye and dry mouth and affecting several 
other organ systems. In Sjögren syndrome (and to a lesser extent NSSDE), the lacrimal gland is infiltrated 
by T-cells, predominantly CD4+ but also cytotoxic CD8+ T-cells; these cluster around acinar epithelial 
cells and induce apoptosis.171 Although primary Sjögren syndrome has been considered to be a T-cell-
driven autoimmune disorder, B-cells also play a key role. IFNα, overexpressed in the salivary gland, may 
induce the production of B-cell activating factor (BAFF) by infiltrating monocytes, dendritic cells and 
resident epithelial cells.172 Immune responses to viral triggers, as well as genetic and hormonal 
influences, may also contribute to inflammatory lacrimal damage. 
 
III.A.4.  Summary and Conclusions 
Hyperosmolarity is a measure of DED severity and distinguishes it from other ocular surface 
disorders. A combination of hyperosmolarity and inflammation leads to keratitis, loss of goblet cells and 
epithelial glycocalyx, with loss of lubrication. Initiating events in DED include ocular surface alterations, 
meibomian dysfunction, lacrimal dysfunction, or a combination of all three; whatever the cause, 
hyperosmolarity is amplified by tear film breakup within the blink interval and further exacerbated later, 
by loss of compensatory feedback. There is an urgent need to improve the understanding of TFLL 
properties and its role in stabilizing the tear film and preventing excessive evaporation. Additionally, 
newer concepts in TFLL barrier properties may lead us to reevaluate our understanding of ADDE and 
EDE. Also needed is a full description of the natural history of dry eye, from hyperosmolarity to the 
initiation of inflammation and its self-perpetuation. Finally, as correlations continue to be poor between 
signs and symptoms, reliable biomarkers are urgently needed, to improve the monitoring and 
management of DED. 
 
III.B. Symptomatology of DED: The Origin of Discomfort (Carlos Belmonte, MD, PhD) 
 
Symptoms of discomfort are integral to the definition of DED.68 However, according to the 2007 
TFOS DEWS report, “the basis for symptoms in dry eye is not truly known but may be surmised from a 
consideration of the etiologies, mechanisms, and responses of dry eye to therapy.” Activation of 
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nociceptors, which form the largest class of corneal sensory neurons, was believed to underlie the 
symptoms of DED. Since the 2007 report, a distinct class of cold thermoreceptors has emerged as an 
additional key modulator of ocular surface sensations and tearing. Dr. Belmonte discussed the functional 
roles of corneal sensory nerves, their altered responses in ocular surface pathology, and their relation to 
the symptoms of dryness, discomfort, and pain in DED and other ocular surface pathologies. 
 
III.B.1.  Functional Roles of Corneal Innervation 
In the human body, the cornea contains the highest density of sensory nerve endings of any 
surface tissue. In normal conditions, a variety of sensations (including pain and discomfort) serve 
physiological roles in maintaining ocular health. In addition to sensory functions, corneal nerves serve 
important protective roles by detecting potentially injurious stimuli and eliciting defensive reflexes (such 
as blinking and lacrimation); moreover, corneal nerves have important trophic functions, including the 
modulation of immune responses and wound healing processes.73 
Impulses at the ocular surface are transmitted to the central nervous system (CNS) via the sensory 
terminals of trigeminal ganglion neurons, which innervate the cornea and conjunctiva. Nerve bundles 
enter the stroma at the corneoscleral limbus, and through repetitive branching give rise to the corneal 
epithelial nerves and the subbasal nerve plexus.173 Functional recordings of corneal sensory activity may 
be performed at various levels, including the CNS (central neurons and analyzing sensations), sensory 
nerves (primarily the peripheral neurons and branches of the trigeminal tract), and at single nerve 
terminals. 
 
III.B.1.a.  Functional characteristics of ocular sensory receptors 
Ocular sensory receptors fall into functionally distinct types, grouped by the nature of their 
specific stimuli and expression of transducing channels.159 Most are nociceptor sensory neurons, which 
are activated by injurious stimuli that evoke corneal pain sensations. Mechanonociceptors and polymodal 
nociceptors respond to mechanical forces, with Piezo2 and TRPA1 as major ion channels.80 Polymodal 
nociceptors also respond to a wide array of additional stimuli, including heat, chemicals, and endogenous 
inflammatory mediators;73, 174-176 major transducing channels include TRPV1-4, TRPA1, and ASICs.80 
The cornea is also innervated by cold thermoreceptors (a class of sensory neurons distinct from 
nociceptors), which confer unique and specific sensory properties to the cornea and conjunctiva. Cold 
thermoreceptors are extremely sensitive to small temperature changes; spontaneously and continuously 
firing at normal background temperatures, they are able to rapidly discern transient temperature 
variations of 0.5°C or less.175, 177 Corneal cold receptor activity depends on TRPM8, two-pore domain K 
channels, and Kv1 channels, which exert opposite influences on thermal threshold, allowing fine-tuning 
of the excitability of cold thermoreceptors.178, 179 There is also evidence suggesting the existence of high-
threshold cold receptors, which detect large temperature variations.180 
 
III.B.1.b.  Evoked sensations and reflex effects 
The cornea is able to distinguish information coming from distinct nerve populations, thus 
discerning different sensations (Figure 6) and evoking various reflexes through specific sensory 
receptors and their respective transducing channels.73 
In polymodal and mechanoreceptive neurons, stimulation results in reflex tearing, blinking, and 
sensations of discomfort (e.g., pain, irritation). Conversely, basal tearing is maintained by cold 
thermoreceptors via TRPM8 channels.179 Basal blinking is likely mediated by cold thermoreceptors as 
well.181 During blinking, tear film dynamics have different effects on ocular surface sensory receptors, 
and cold thermoreceptors seem to convey sensory information regarding ocular surface dryness. 177 
Thermoreceptors expressing TRPM8 channels are also activated by increased osmolality and inhibited by 
reduced osmolality; furthermore, Trpm8-/- mice display reduced blinking compared with wild-type mice, 
suggesting that TRPM8 has osmosensory functions in the regulation of normal blinking.181 As discussed 
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in the previous section, during the interblink periods, spots of ocular surface cooling coincide with tear 
film breakup, and reflect local increases in evaporation.141 Prolonged eye opening or enhanced corneal 
evaporation may result in further temperature decreases and thus more cold fiber activity.159 
Experimentally, cold thermoreceptors have been shown to be activated by ocular surface drying and 
hyperosmolarity.182 It is possible that ocular surface sensory receptors are stimulated by tear film 
breakup, with stimulation of cold thermoreceptor activity with decreases in ocular surface temperature 
and increases in osmolarity, and nociceptor activation with increased mechanical stress and injury of 
epithelium cells. 
 
III.B.2.  Sensory Receptor Responses in Ocular Surface Pathologies 
In contrast to the aforementioned sensory receptor responses that are part of normal 
physiological processes, altered activation occurs in inflammation and peripheral nerve injury. These two 
pathological processes are often inextricably linked, and depending on the level (and duration) of 
inflammation and/or injury, symptoms may differ in terms of evoked sensations. 
In polymodal nociceptors, inflammatory mediators can cause excitatory increases and 
sensitization.174 This occurs through the opening of TRPV1 and TRPA1 ion channels, resulting in 
membrane depolarization, sensitization of nociceptor endings, and hyperesthesia—and thus an 
augmented response to virtually any stimulus. Chronic inflammation can further cause long-term 
changes in ion channel expression, perpetuating this situation and evoking chronic inflammatory pain.80 
Nerve injury from a variety of causes (including physical damage, toxicity, and infection) may lead to 
inflammation; however, in many cases (such as in ocular surgery), ocular nerves are directly severed or 
destroyed, and the effects of nerve damage can persist beyond transient inflammation. After surgery-
induced nerve damage, an immediate reduction in corneal sensitivity is followed by transient 
hyperesthesia to mechanical stimuli; 3–5 months later, there is hyposensitivity to both mechanical and 
chemical stimuli,183 and further central neural aberrations may result in neuropathic pain.80 
Whereas polymodal nociceptors are sensitized by inflammatory mediators released during 
inflammation, an “inflammatory soup” (including mediators such as bradykinin, prostaglandins, and 
histamine) inhibits TRPM8 in cold thermoreceptors, thus reducing cold-evoked activation.184 Nerve 
injury to cold thermoreceptors markedly increases their ongoing activity at 34°C. Like polymodal 
nociceptors, changes have been surmised to involve alterations in the expression of ion channels.80 
In pathological conditions of the ocular surface, varying levels of inflammation and nerve injury 
result in various symptoms of discomfort (Figure 7). Symptomologies will arise from the specific 
aberrations in the impulse activity of sensory nerve pathways, resulting in typical sets of symptoms for 
different ocular surface pathologies. 
 
III.B.2.a  Dry eye disease 
Uncomfortable dryness is a defining feature of DED.68 Ocular surface inflammation and damage 
likely evoke sensations of discomfort and pain through polymodal nociceptors; additionally, lid action 
over a dry ocular surface is likely to result in activation of mechano- and polymodal nociceptors.73 Cold 
thermoreceptors may play an even greater role in evoking unpleasant dryness sensations, as they are 
activated by evaporation-induced cooling179 and, importantly, by hyperosmolarity,185 a core mechanism 
of DED. These notions are supported by recent evidence from a DED model, in which lacrimal gland 
removal resulted in transient inflammation and polymodal nociceptor sensitization, yet progressive and 
ongoing activation of cold thermoreceptors after inflammation subsided.186 
 
III.B.2.b.  Refractive surgery 
Refractive surgery causes injury to corneal sensory nerve endings,187 and dry eye is a common 
complication of refractive procedures despite the lack of dramatic changes in tear dynamics.90 The effects 
of inflammation are minimal compared to the nerve damage, which alters the transducing capacity of 
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mechano- and polymodal nociceptors, resulting in pain immediately after photorefractive surgery188 and 
loss of mechanical and chemical sensitivity.183 In contrast, cold thermoreceptors display abnormally high 
background firing and warmer thresholds for cooling following refractive surgery.80 Thus, postsurgical 
sensations of dryness may be more neuropathic in origin, and less related to tear film deficiency.79, 90 
 
III.B.2.c.  Allergic conjunctivitis and UV-induced keratitis 
Allergic conjunctivitis comprises several forms, and generally involves allergen-triggered release 
of inflammatory cytokines and associated symptoms of swelling and irritation.68 In a model of 
experimental allergic conjunctivitis, mechano- and polymodal nociceptors were sensitized,189 while low-
threshold cold thermoreceptors displayed reduced activity, presumably due to the inhibition of TRPM8 
by inflammatory mediators.184 An experimental model of UV-induced keratitis resulted in a similar 
profile of nociceptor sensitization and suppression of cold thermoreceptor activity (likely due to the 
inhibitory effects of inflammatory mediators on TRPM8 channels).190 Taken together, these response 
profiles are likely to produce the symptoms of discomfort in conjunctivitis and UV-induced keratitis. 
 
III.B.3.  Summary and Conclusions 
Although ocular surface pathologies have diverse etiologies, their symptoms often converge on 
altered responses of corneal sensory nerves. Distinct symptomologies arise from the varying involvement 
of mechanonociceptors, polymodal nociceptors, and cold thermoreceptors. In recent years, there have 
been significant advances in the understanding of cold thermoreceptors and their roles in ocular surface 
disorders. Furthermore, several lines of investigation have yielded great insight into the molecular 
physiology of nociceptors and thermoreceptors, their alterations in pathological processes, and the 
specific sensations evoked in ocular surface disorders. Future research should try to define the molecular 
sensors involved in the activation and modulation of the various classes of sensory nerve fibers 
innervating the ocular surface and identify the phenotypic changes that develop under different 
pathological conditions. It is also important to determine the contribution of each functional class of 
ocular sensory receptor to the subjective characteristics of the unpleasant sensations evoked by such 
pathological processes. Finally, research oriented to the pharmacological control of the abnormal activity 
displayed by corneo-conjunctival sensory receptor terminals is required. Selective manipulation of 
peripheral sensory input to the brain is possibly the most efficacious way of reducing eye discomfort and 
pain without the side effects that often accompany administration of drugs targeting central nervous 
system pain pathways.  
 
III.C.  Diagnosis of Dry Eye Disease (James Wolffsohn, OD, PhD) 
The 2007 report of the TFOS DEWS Diagnostic Methodology Subcommittee provided a thorough 
assessment of DED parameters, and compiled and validated a comprehensive database of assessment 
techniques for disease diagnosis and monitoring.2 Prof. Wolffsohn reviewed the 2007 report and the 
current state of DED diagnosis, including remaining unmet needs, recent advances, and novel testing 
approaches. 
 
III.C.1.   Current State of DED Diagnosis 
DED is a multifactorial disease with many subtypes;68 as such, accurate diagnosis is heavily 
dependent on robust criteria for defining and classifying the disease. However, the definition of DED has 
evolved since the1995 Report of the National Eye Institute (NEI)/Industry Dry Eye Workshop,191 which 
defined DED as follows: 
“Dry eye a disorder of the tear film due to tear deficiency or excessive evaporation, which causes 
damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort.” 
Subsequently, the 2007 TFOS DEWS report updated the definition and classifications of DED 
based on etiology, mechanisms, and severity:68 
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“Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. 
It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.” 
The TFOS DEWS Diagnostic Methodology Subcommittee (representing a global collaboration of 
scientists, clinicians, and industry representatives) reevaluated the available diagnostic tests in the 
context of the contemporary understanding of DED, including the updated definition. These efforts 
resulted in a searchable database of tests for diagnosing and monitoring DED, with individual tests 
compiled and assessed by experts in the field and presented within standard templates (available at 
www.tearfilm.org/dewsreport).2 The DEWS report highlighted the importance of differential diagnosis of 
dry eye vs. non-DED, as well as their subtypes, which are not mutually exclusive and may be interrelated 
(Figure 8). 
In light of the updated definition and classifications of DED, the DEWS Diagnostic Methodology 
Subcommittee determined that among the numerous tests that are currently used for diagnosing and 
monitoring DED, non-invasive tear film break-up time (NITFBUT) likely represented the best means of 
evaluating tear film stability for office-based physicians, with moderately high sensitivity and good 
overall accuracy.2 However, an objective measure of dry eye hyperosmolarity was still desired. 
Furthermore, available tests were hindered by shortcomings such as selection bias (introduced by the 
method used for selecting subjects in an experiment) and spectrum bias (due to differences in the 
features of different populations, which influence the sensitivity and/or specificity of a test). 
Although there have been recent advances for eye care practitioners regarding differential 
diagnosis, particularly for MGD/blepharitis (Figure 9),192, 193 Sjögren’s syndrome,194 and contact lens-
associated DED,195 it remains difficult to tease out the different subtypes of DED in the clinic. In pharmacy 
settings, “mystery shopper” studies have shown that differential diagnosis of DED and other ocular 
surface disorders is particularly poor.196, 197 Finally, it is not entirely clear whether performing multiple 
tests will have additive diagnostic value. For example, in a recent evaluation of multiple dry eye tests, we 
found that various tear stability tests and likewise tear volume tests and ocular surface damage tests 
produced largely comparable results (suggesting that a single test in each ‘category’ may suffice), and the 
predictive values of different treatments may vary depending on the outcomes evaluated.198 
For a multifactorial disease with variable phenotypes such as dry eye, a strong definition and 
classification scheme is necessary to drive diagnosis, epidemiology, clinical trial design, and basic 
scientific research. Additionally, for a diagnosis to be useful, it would need to be able to inform 
management of different forms of DED. However, this continues to be challenged by the persistent lack of 
uniform concepts and minimum sets of diagnostic criteria for DED and its subtypes. This is illustrated by 
the variable methods used in epidemiological studies reviewed in the 2007 report of the TFOS DEWS 
Epidemiology Subcommittee,3 as well as in Section II of this report. A strong definition of DED would 
form a solid foundation on which to base diagnostic methodologies of DED, which would in turn facilitate 
management, research, and clinical development of effective therapeutic strategies. 
 
III.C.2.   Assessments Based on the Current Definition of DED 
Several diagnostic test categories for DED, discussed briefly here, are based on five factors 
included in the current definition of the disease (emphases added): 1) symptoms of discomfort, 2) visual 
disturbance, 3) tear film instability with potential damage to the ocular surface, 4) increased osmolarity of 
the tear film, and 5) inflammation of the ocular surface. The current definition requires each of these 
factors to be present for dry eye to occur, but this was not articulated in the subsequent diagnosis report 
or in subsequent research studies, limiting the ability to better understand and develop treatments for 
dry eyes and its sub-classification conditions. Damage to the ocular surface (qualified by the operative 
word “potential”), and other factors not included in the current definition of DED, are discussed in the 
following section. Most of the assessments for these diagnostic test categories were described in detail in 
the 2007 report of the TFOS DEWS Diagnostic Methodology Subcommittee.2 
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III.C.2.a.  Symptoms 
Symptoms of discomfort are the foremost defining factors of the current definition of DED.68 
Symptomology also forms the basis of validated dry eye questionnaires, which are noninvasive, highly 
accessible, and widely used in the clinic and in population-based studies. Surveys used for diagnosing 
DED (and recommendations for their use in clinical trials) were detailed in the 2007 report of the TFOS 
DEWS Epidemiology Subcommittee.3 Questions include supplementary history (e.g., age and gender, 
systemic conditions/atopy, medication, environment, and smoking), which often relates to risk factors 
for DED. Many dry eye questionnaires, such as the McMonnies questionnaire,199 utilize a systematic 
approach for diagnosing DED. Others, such as the Ocular Surface Disease Index© (OSDI©),200 have been 
adapted to smart phones and tablets, which appeals to patients because they facilitate self-monitoring 
and regular feedback. Other notable questionnaires include the Dry Eye Questionnaire (DEQ)50, 201, 202 and 
the survey of 39,876 women participating in the U.S. Women's Health Study, which involved only three 
questions.17 
 
III.C.2.b.  Visual disturbance 
Although visual disturbance is included in the 2007 DEWS definition of DED, it is often dismissed 
by patients as a normal course (e.g., aging), and usually this symptom is only revealed through certain 
questionnaires.2 There is also a paucity of research on objective measures of visual disturbance in DED. 
The 2007 report of the TFOS DEWS Diagnostic Methodology Subcommittee mentioned one functional 
measurement system for assessing dynamic visual acuity changes,203 and a recent study comparing two 
ocular lubricants (or a combination of the two) found no significant differences in visual quality or higher 
order aberrations.204 Better objective measures of visual disturbance are still needed in the evaluation of 
DED. 
 
III.C.2.c.  Tear film instability 
Tear film stability has been a major cornerstone of clinical tests for dry eye, with the main metric 
being TFBUT. Fluorescein is often instilled to enhance visibility of the tear film, and this mildly invasive 
tear stability measurement is often referred to as the fluorescein break-up time (FBUT). There is 
significant variability among reference values for dry eye diagnosis, ranging from the longstanding cut-off 
time of <10 seconds,205 to the more-recently proposed cut-off time of <5 seconds for smaller volumes of 
fluorescein.206 Non-invasive TFBUT was determined by the DEWS Diagnostic Methodology Subcommittee 
as likely the best assessment of tear film stability for eye care practitioners, with moderately high 
sensitivity (83%) with good overall accuracy (85%),2 and may be measured noninvasively with 
instruments such as the Tearscope. We have found highly correlated results from non-invasive 
keratograph break-up time (NIKBUT – although tear instability is generally detected more quickly with 
objective methodology), Tearscope NIBUT, and FBUT tear stability tests, suggesting that the predictive 
value of FBUT may be redundant with less invasive tests.198 
 
III.C.2.d.  Osmolarity 
Tear osmolarity, which has long been considered to be a possible “gold standard” of dry eye 
diagnosis, was introduced as a defining measure of DED in the 2007 TFOS DEWS report.68 However, an 
objective measure of dry eye hyperosmolarity was still lacking at the time.2 For diagnosis of DED, a 
reference limit of 316 MOsm/L is generally accepted,207 yet the widespread utility of osmolarity testing 
has been limited by the lack of reliable measurement techniques.  
The development and validation208-211 of a commercial osmometer, the TearLab Osmolarity 
System, has significantly advanced the diagnosis and management of DED based on osmolarity. A tear 
osmolarity >308 mOsm/L is considered as the appropriate cut-off of DED, with the maximum of two eyes 
used in the diagnosis, acknowledging heteroscedasticity as an indicator of tear film instability.212 Since 
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the initial DEWS report, osmolarity has been shown not to be strongly associated with other tear film 
metrics such as TFBUT,213-215 but has been shown to be more sensitive to diagnosing dry eyes in 
general145, 216, 217 and dry eyes induced by other conditions (such as LASIK,218 type 2 diabetes,219-221 and 
rheumatoid arthritis222) and identify patients who are more likely to have unexpected refractive errors 
following cataract surgery due to disruption of the ocular surface when performing pre-operative 
biometry.223 It has also been shown to be sensitive to detecting and monitoring graft vs. host disease.224, 
225 With effective treatment of most dry eye-related conditions, tear film osmolarity returns to normal 
and its variability reduces.126 It has recently been recommended as a test to inform the clinical 
management of Sjögren disease.226 
 
III.C.2.e.  Inflammation 
DEWS diagnostic templates have been developed for bulbar hyperemia scales, which may be used 
to assess the degree of redness (due to vessel dilation) of the bulbar conjunctiva. Although such scales 
have helped with quantifying ocular surface inflammation, it remains a “noisy” subjective measure, and 
the natural phenomenon of whole number bias may further limit the accuracy and sensitivity of these 
subjective scales. Prior to the 2007 DEWS report, we developed methods for monitoring ocular 
physiology, including hyperemia, using objective image analysis,227-229 and recent studies have 
demonstrated greater sensitivity and reliability compared to subjective grading methods.230 Further 
development may result in the adoption of these objective measures and integration with current 
techniques for assessing ocular surface inflammation.231 Other new approaches for evaluation of ocular 
surface inflammation include point-of-care testing for inflammatory biomarkers. One such test by Rapid 
Pathogen Screening, Inc. (RPS) detects tear levels of both active and latent MMP-9 (test cutoff value of 40 
pg/mL), an inflammatory marker that has been shown to be elevated in DED.232, 233 However, initial 
research suggests MMP-9 is only detected in late stage dry eye,233 in a similar manner to fluorescein 
staining (Bron et al., 2015).234 
 
III.C.3.  Other Assessments of DED 
A number of tests for DED are based on factors that under the current definition are not absolute 
characteristics of the disease. Nonetheless, because there is no single definitive test or diagnostic battery 
for DED, these tests may be complementary and/or aid in evaluating disease severity. Moreover, some 
measures obtained in certain tests may affect the interpretation of other test outcomes. 
 
III.C.3.a.  Damage to the ocular surface 
Whereas “damage to the interpalpebral ocular surface” was a defining feature of DED in the1995 
Report of the NEI/Industry Workshop,191 one notable distinction of the 2007 TFOS DEWS report was the 
qualification of “potential damage to the ocular surface” in DED.68 Nonetheless, it is common practice to 
assess ocular surface damage by grading staining by fluorescein dye, lissamine green or (to a lesser 
extent) rose bengal. 
Fluorescein was described in 1882 by Pflüger for evaluating the corneal & conjunctival abrasions 
in rabbits,235 and its first clinical use is attributed to Fromm & Groenouw in 1891.236 Today, fluorescein is 
the most widely used diagnostic dye by eye care practitioners, and the longstanding belief is that 
fluorescein highlights defects in the corneal and conjunctival epithelium by specifically entering damaged 
cells. However, in a recent critical review of the literature,237 alternative cellular mechanisms that may 
cause corneal fluorescence were examined, beyond the previously suggested surface pooling, such as 
cellular uptake, and ingress around cells due to disruption of cell-cell junctions.238 Thus, a better 
understanding of the mechanisms of fluorescein staining may alter the interpretation of this diagnostic 
method. In a recent review,234 Bron and colleagues noted that a proportion of normal corneas show 
sparse, scattered time-dependent, punctate fluorescein uptake, which they hypothesize is due to a graded 
loss of the glycocalyx barrier, permitting transcellular entry into pre-shed cells. The minimal or absent 
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epithelial damage noted in short break-up time dry eye in symptomatic office workers who use visual 
display units suggests that corneal staining may onset relatively late in the development of DED.239 
Lissamine green was introduced in 1973 by Norn,240 and has been demonstrated to stain 
membrane-degenerate cells and dead cells; furthermore, lissamine staining is not blocked by mucin.241 
Lissamine green stains the ocular surface in a manner similar to rose bengal (although rose bengal is 
blocked by mucin242), but with less irritation and toxicity to eyes.243 Because it fades within four minutes, 
repeat instillation of 10-20μl of lissamine are required.244 In a recent evaluation of the efficacy of 
fluorescein, rose bengal, lissamine green for ocular surface staining, a mixture of 2% fluorescein and 1% 
lissamine green was found to be superior to individual dyes.245  
 
III.C.3.b. Tear volume 
 
The phenol red thread test provides an index of tear volume, and likewise Schirmer testing (with 
or without anesthesia or nasal stimulation) provides an assessment of tear secretion. Newer techniques, 
such as the use of smart phones or tablets for assessing tear meniscus curvature and its relationship to 
tear volume,246 may provide reliable and sensitive (yet noninvasive) estimates of tear volume. 
 
III.C.3.c.  Lid parallel conjunctival folds 
Lid parallel conjunctival folds (LPCOFs or LIPCOFs) are subclinical folds in the lateral, lower 
quadrant of the bulbar conjunctiva, parallel to the lower lid margin, and may be predictive of dry eye.247, 
248 They are evaluated by slit lamp (typically using a 2-3 mm vertical slit, 18-24x magnification, and angle 
20°-30°). Of note, LIPCOFs may cause tear meniscus height measurements to be underestimated,157 
which is an important consideration when interpreting estimates of tear volume. 
 
III.C.3.d.  Lid wiper epitheliopathy 
The lid wiper is the edge (0.4-0.6mm wide) of the marginal conjunctiva of the upper eyelid, which 
slides over ocular surface, during blinking, approximately 8,000 times per day. Noting that the epithelium 
of the lid wiper is squamous (not columnar), Parsons suggested that the lid wiper is the only part of the 
conjunctiva that closely contacts the ocular surface.249 Sequential instillations with dyes (e.g., fluorescein, 
lissamine green, or rose bengal) stains the lid wipers of the majority of patients with symptomatic DED, 
and grading is typically based on horizontal length of staining or a combination of length and width.156, 250 
Lid wiper epitheliopathy is commonly found in patients experiencing symptoms of DED, but displaying 
normal findings with other tests (e.g., FBUT, Schirmer test).156 It has been reported that 80% of 
symptomatic contact lens wearers (vs. 13% of asymptomatic lens wearers) have staining indicative of lid 
wiper epitheliopathy,156 and that damage increases after 6 months of lens wear, although other tests such 
as tear volume assessed by the phenol red test remains constant.198 Of note, assessment of LWE requires 
understanding of Kessing’s space, which separates the ocular surface from tarsal palpebral conjunctiva of 
the upper eyelid.248 
 
III.C.4.  Summary and Conclusions 
Achieving a robust, comprehensive diagnostic battery remains an important clinical challenge for 
DED. Due to the inherent heterogeneity of the disease itself and the populations affected, this requires 
clear definitions of disease subtypes and unbiased physiological ranges of what is ‘normal’ adjusted for 
demographics. Other significant considerations include invasiveness and cost effectiveness (both in 
terms of consumable costs and requirements for time and skills). For a comprehensive diagnostic battery, 
it is also paramount to evaluate the usefulness of each component in order to optimize diagnostic yield 
and to better inform treatment. 
 
IV. TREATMENT CHALLENGES OF DED 
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IV.A.  New Approaches for the Treatment of DED (David A. Sullivan, MS, PhD, FARVO) 
Despite the fact that hundreds of millions of people throughout the world suffer from DED, there is 
no approved global cure for this condition. Dr. Sullivan noted that, whatever the cause, the final common 
denominators of DED are tear film hyperosmolarity and instability (Figure 4).1 Hyperosmolarity induces 
the symptoms of discomfort by acting on the cold thermoreceptors of the cornea (See Section III.B. 
Symptomatology of DED). Hyperosmolarity also causes loss of epithelial cell surface microplicae, which 
were first described in 1976 and postulated to hold a protective layer of mucin.251 Loss of the microplicae 
results in loss of the negative charge of the glycocalyx,252 detrimental effects on tear film stability, and 
further increases in evaporation.253 Ultimately, tear hyperosmolarity leads to a “vicious circle” of 
increased ocular surface stress, friction, inflammation and damage, and visual impairment.140 
Dr. Sullivan highlighted a number of new therapeutic approaches for DED, which target either the 
underlying disease mechanisms or their sequelae. Dr. Sullivan also reviewed shared attributes of failed 
interventional trials for DED, underscoring the unmet needs in appropriate disease indicators and 
preclinical models. 
 
IV.A.1.  Approved Treatments for DED 
Very few treatments for DED, described briefly below, have achieved approval by regulatory 
agencies in certain countries. 
 
IV.A.1.a.  Cyclosporine A (Restasis®, Ikervis®) 
Cyclosporine A ophthalmic emulsion 0.05%, manufactured by Allergan, Inc. and marketed as 
Restasis®, is the only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment 
of DED,254 with estimated net sales of $1 billion in 2014.255 According to the U.S. package insert,256 
“Restasis is indicated to increase tear production in patients whose tear production is presumed to be 
suppressed due to ocular inflammation associated with keratoconjunctivitis sicca” and has demonstrated 
significant increases (~10 mm) in Schirmer wetting in 15% of treated patients vs. 5% of vehicle treated 
patients.257 Restasis® was approved in December 2002 by the FDA after post-hoc data analyses. A topical 
formulation of cyclosporine A, marketed as Ikervis® by Santen (formerly known as Novagali Pharma), 
was recently made available in Europe (discussed in Section IV.C). 
 
IV.A.1.b.  Diquafosol (Diquas™, Prolacria™) 
Diquafosol is a P2Y2 purinergic receptor agonist that stimulates conjunctival fluid flow and mucin 
secretion.258 In 2010, diquafosol tetrasodium ophthalmic solution 3% (Santen Pharmaceutical Co., Ltd.) 
was approved for dry eye treatment in Japan, where it is marketed as Diquas™.259 However, in the United 
States, diquafosol tetrasodium 2% (Prolacria™, Inspire Pharmaceuticals, Inc.) did not achieve primary 
and secondary endpoints in Phase III clinical trials,260 and it did not achieve FDA approval. 
 
IV.A.1.c.  Rebamipide (Mucosta™) 
Rebamipide is a quinolinone derivative that induces mucus secretion by activating cyclooxygenase 
2, and has been shown to decrease lissamine green conjunctival staining and foreign body sensation, as 
compared to 0.1% sodium hyaluronate.261, 262 In Japan, rebamipide is approved and marketed for the 
treatment of dry eye syndrome as Mucosta® Ophthalmic Suspension UD2%. However, Phase III trials by 
Novartis263, 264 and Acucela, Inc.265 did not appear to provide at least two well-controlled, replicative 
studies showing efficacy in the United States. 
 
IV.A.1.d.  Hyaluronate (Hyalein®) 
Topical sodium hyaluronate 0.3%, marketed by Santen Pharmaceutical Co., Ltd. as Hyalein®, was 
introduced in 1995 as Japan’s first treatment for disorders of the cornea and conjunctival epithelium. 
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River Plate pursued an NDA for sodium hyaluronate in the treatment of keratoconjunctivis sicca. An FDA 
advisory committee meeting recommended against approval in July 2009. While sodium hyaluronate for 
dry eye treatment is regulated as a drug in the United States, some manufacturers have included it as an 
excipient in over-the-counter (OTC) eye drops. OTC preparations are also widely available in numerous 
countries in Asia and Europe.266 
 
 
IV.A.2.  New Treatment Targets 
The underlying pathophysiology of DED, described in Section III.A and illustrated in Figure 4, 
provides several potential treatment targets for DED. Indeed, more than 200 interventional clinical trials 
for the treatment of DED have been registered since 2010 (see Section II.A: Epidemiology of DED). New 
therapeutic strategies (with varying levels of supportive evidence) may be classified based on these 
targets, and are summarized below. 
 
IV.A.2.a  Symptoms of discomfort 
Symptoms of discomfort are fundamental to the definition of DED,68 and arise from various 
pathological processes (see Figure 4) and converge on altered responses of corneal sensory nerves. 
Acupuncture and traditional Chinese medicine have been suggested to relieve dry eye symptoms by 
stimulating tear secretion and/or decreasing pain, while more-recently developed treatments aim to 
decrease pain by targeting major transducing channels of ocular sensory receptors (Table 8). 
 
IV.A.2.b.  Mucin deficiency 
Hydrophilic mucins are critical for holding tears onto the ocular surface, and alterations in mucin 
levels have been demonstrated in DED.275 Various therapeutic approaches have aimed to stimulate, 
stabilize, or mimic mucins on the ocular surface (Table 9). 
 
IV.A.2.c.  Aqueous tear deficiency 
Multiple pathological processes promote aqueous tear deficiency (see Figure 4), and artificial 
tears form the largest treatment class for this condition, with a market that is expected to exceed $2 
billion USD by 2018.289 Other treatment strategies that target tear deficiency include tear 
supplementation, hydration, tear film conservation, and aqueous tear stimulation (Table 10). Of note, 
vitamin A metabolites have been proposed to increase the Schirmer wetting score,290 but are also known 
to cause MGD and evaporative DED.291 
 
IV.A.2.d.  Epithelial cell desiccation 
Several osmoprotectants have been proposed to improve cell water management, avoid cell 
membrane lipid oxidation and protein denaturation, and preserve epithelial cell life in hyperosmotic 
conditions. (Table 11). Combination formulas containing osmoprotectants (along with other agents) have 
also been reported to alleviate ocular symptoms and staining in patients with DED.312 
 
IV.A.2.e.  Mitochondrial oxidation 
A small molecule SkQ1 (also called Visomitin or plastoquinonyl decyltriphenyl phosphonium) has 
been engineered to reduce oxidative stress inside mitochondria (Table 12), with the goal of decreasing 
the apoptosis of ocular surface epithelial cells during aging.322 This topical drug is currently in DED 
clinical trials in the United States.323 An ophthalmic formulation of Visomitin is already marketed in 
Russia.324 
 
IV.A.2.f.  Ocular surface inflammation 
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As defined in the TFOS Dry Eye WorkShop (DEWS) report,68 “Dry eye is a multifactorial disease of 
the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film 
instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the 
tear film and inflammation of the ocular surface.” This DED association with inflammation, especially 
given the approval of Restasis by the USA FDA, has led to the development of numerous anti-
inflammatory compounds for possible use in DED treatment (Table 13). However, despite this effort, 
interventional clinical trials of anti-inflammatory and immunomodulatory agents have invariably failed 
to meet their primary endpoints (e.g. typically corneal fluorescein staining; discussed later). 
 
IV.A.2.g.  Meibomian gland dysfunction 
Meibomian glands play an extremely important role in the health and well-being of the ocular 
surface. The acinar epithelial cells of these glands secrete a proteinaceous lipid mixture (i.e., meibum) 
that promotes the stability and prevents the evaporation of the tear film.123 Conversely, MGD, and the 
resulting meibum insufficiency, destabilizes the tear film, increases its evaporation and osmolarity, and is 
the most common cause of DED (Figure 10).123 
The 2011 TFOS MGDW Subcommittee on Management and Treatment recommended treatment 
options for various stages of MGD.329 In the United States, azithromycin (used off label) is the most 
common treatment for MGD,330 and was thought to decrease inflammation and bacterial growth. Recent 
studies have shown, though, that azithromycin’s efficacy may also be due to stimulating the function of 
meibomian gland epithelial cells.331, 332 Tetracycline-based antibiotics do not duplicate these 
azithromycin actions on human meibomian gland epithelial cells.333 
Another MGD treatment approach is topical testosterone, given that androgen deficiency is a 
significant risk factor for the development of MGD.162, 334, 335 Topical testosterone drops were tested in a 
Phase 2 clinical trial by Allergan and reportedly led to a significant decrease in the signs and symptoms of 
MGD.336 Allergan has recently continued these trials in the United States. 
Figure 10 illustrates the events that cause progression of MGD to a self-propagating, chronic 
condition, and represents multiple new therapeutic approaches, summarized in Table 14. 
 
IV.A.2.h.  Ocular surface stress 
DED hyperosmolarity leads to increased ocular surface friction and stress. Recent studies have 
suggested that lubricin, an anti-friction and anti-adhesion protein, may serve as an important barrier to 
the generation of such friction and stress, and especially the corneal and conjunctival epitheliopathies 
that occur in DED 7, 8 If so, then topical lubricin could prevent the DED-associated downstream 
development of ocular surface inflammation and damage (Table 15). A clinical trial is currently underway 
in Europe to evaluate the therapeutic potential of lubricin in alleviating DED. 
 
IV.A.3.  Reasons for Failure in Clinical Trials for DED 
Despite supportive preclinical evidence, the vast majority of therapeutic candidates for DED have 
failed in clinical trials. The low success rate may be due to the multitude of potential confounders, 
including clinical trial length (in relation to time taken to reverse end points), numerous environmental 
factors, heterogeneity in study populations (e.g., age, gender, comorbidities), and the heterogeneity of 
DED itself (in terms of causes, symptoms, and clinical manifestations). While some trials of potential 
therapies (such as rebamipide350 and pimecrolimus351) have ended quietly with little explanation, the 
results of other failed studies have highlighted overarching issues that plague clinical trials for DED. 
 
IV.A.3.a. Dependence on corneal staining 
Although some clinical trials for DED have met certain co-primary or secondary endpoints, the 
vast majority of studies have failed to meet endpoints related to corneal staining (Table 16). Corneal 
staining is generally accepted as a sign of ocular surface damage (and therefore indicative of DED); 
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however, it is important to note that corneal staining does not occur in all cases of dry eye, nor is it 
sufficient to diagnose DED under the current definition,68 as discussed in Section III.C of this report. 
Finally, corneal staining may not be the most robust measure of dry eye severity.145, 217 Therefore, the 
dependence on corneal staining to assess treatment response may confound the interpretation of clinical 
trial results. 
 
IV.A.3.b.  Lack of correlation between clinical signs and symptoms 
Although symptoms of discomfort are the foremost feature in the current definition of DED,68 
symptoms alone are insufficient for the diagnosis or management of DED, and their subjective nature 
limits the sensitivity of symptom scores for assessing treatment response. Furthermore, for DED, the 
correlation between signs and symptoms is notably poor,352 as is the correlation among individual dry 
eye tests.213 This lack of correlation between the signs and symptoms of DED complicates the clinical 
evaluation of candidate therapies. It may be that a consensus of clinical signs may better reflect all 
aspects of the disease.213 
 
IV.A.3.c.  Dependence on murine preclinical models 
For many human conditions, murine models have been invaluable for elucidating the underlying 
physiological and pathological processes. However, therapeutic candidates that have been identified and 
preclinically validated in mouse models do not always translate successfully to humans. This is may be 
particularly true for therapies targeting inflammatory pathways, as genomic responses to inflammatory 
challenges have shown poor correlation between different mouse models in comparisons with human 
responses.364 Although some studies show that mouse results can be predictive of therapeutic success in 
humans,365, 366 the fact remains that dozens of clinical trials involving investigational anti-inflammatory 
therapies based on mouse data have failed, including several potential treatments for DED (Table 16). 
These findings underscore the need to demonstrate whether a mouse model mimics, or fails to mimic, a 
relevant human disease.364, 367, 368 
 
IV.A.4.  Summary and Conclusions 
 
A major unmet need in the treatment of DED is the lack of effective global treatments. Recent 
advances in the understanding of underlying pathological processes have uncovered novel disease 
targets, which may lead to innovative therapeutic strategies for this complex disease. Clinical trials of 
candidate therapies, though largely unsuccessful to date, have provided insight for future lines of 
investigation and therapeutic development—emphasizing the need for caution when extrapolating basic 
scientific findings from animal models to human therapies. 
 
IV.B.  Regeneration of the Ocular Surface in Severe DED (Stefan Schrader, MD, PhD) 
 
Dry eye is a disease with many different causes, as described in the 2007 report of the TFOS DEWS 
Definition and Classification Subcommittee68 and elsewhere in this report (see Section III.C. and Figure 
8). As such, multiple pathologic mechanisms can interact and synergize to damage the ocular surface 
(Figure 4). 
For DED, most available therapies either aim to relieve symptoms or to curb inflammation of the 
ocular surface (see Section IV.A, New Approaches for the Treatment of DED). Although these treatment 
strategies are targeting fundamental attributes of DED, they do not fully address the unmet needs in 
disease management—especially in severe cases. By definition, symptomatic treatments do not address 
the underlying cause(s) of disease; furthermore, immunomodulatory treatments are largely targeting the 
final, self-propagating pathways of DED, and might only serve to prevent or slow the progression of 
damage. A more meaningful approach would target the specific causes of DED and regenerate damaged 
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structures—thus reversing the pathological processes. To this end, three approaches are presented for 
regenerating the ocular surface and adnexa in severe DED: 1) support of regeneration by a “tear-like” 
substitution, 2) regeneration/reconstruction of secretory tissue, and 3) regeneration/reconstruction of 
the ocular surface itself. 
 
IV.B.1.  Support of Regeneration by “Tear-Like” Substitution 
The ocular surface environment contains an array of growth factors, which suggests that they 
support tissue maintenance and wound healing. Artificial tears, which form the largest treatment class 
for DED, improve lubrication and hydration; however, they lack the biological properties of natural 
tears.369 Thus, a more tear-like substitution may be necessary to support regeneration of the ocular 
surface. 
 
IV.B.1.a.  Autologous serum 
Like natural tears, the serum contains numerous growth factors, including epidermal growth 
factor (EGF), transforming growth factor beta (TGF-β), keratinocyte growth factor (KGF), hepatocyte 
growth factor (HGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF); thus, 
autologous serum has been considered for potential therapeutic use in ocular surface disorders.370 The 
clinical use of autologous serum to support corneal regeneration can be traced to the mid-1970s, when 
Ralph, Doane, and Dohlman perfused various fluids (including autologous and homologous sera) to the 
ocular surfaces of patients following keratoplasty, severe chemical burns, or lid/fornix reconstruction for 
severe DED.371 About a decade later, artificial tears containing autologous serum were reported to have 
beneficial effects for keratoconjunctivitis sicca.372 In 1999, autologous serum was reported to improve 
ocular surface staining (rose bengal and fluorescein) in Sjögren’s syndrome373 and to successfully treat 
persistent epithelial defects.374 This triggered more widespread use of serum eye drops as topical 
epitheliotrophic treatments, and optimized protocols were developed for the production of autologous 
serum for this purpose.375 Serum has also been successfully used in combination with other therapies. 
For example, combined with hydrogel bandage contact lenses, autologous serum eye drops demonstrated 
a significant improvement of healing of persistent epithelial defects.376 
However, in the growing body of literature evaluating autologous serum for DED, there has been 
mixed evidence of success in terms of clinical utility. The efficacy of autologous serum was evaluated in 
the 2007 report of the TFOS DEWS Management and Therapy Subcommittee,4 which found that the 
efficacy of serum eye drops for DED varied substantially between studies.373, 377-380 In addition to 
significant variations in patient populations, there have been large disparities in production, storage, and 
treatment protocols.375 The most convincing evidence of success has been for the treatment of persistent 
epithelial defects, in which efficacy is more evident in “healing” of the defects.381 For objective measures 
of DED, the benefits are less clear. A recent randomized, double-blind, crossover clinical trial 
demonstrated improvement in symptoms after short-term autologous serum compared to artificial tears 
(Systane®), but no change in objective parameters such as TFBUT and Oxford score for corneal and 
conjunctival fluorescein staining.382 A recent Cochrane systematic review and meta-analysis, published in 
2013, found inconsistency in the potential benefits of autologous serum on TFBUT and subjective 
symptoms, and overall lack of effect based on objective clinical measures.383 To properly evaluate the 
benefits of autologous serum for DED, well-designed studies are warranted, using standardized 
questionnaires, reliable objective assessments, and objective biomarkers. To further complicate the 
evaluation of autologous serum, it is not only difficult to compare different trials but also individual 
patients within trials, as serum epitheliotrophic/anti-inflammatory factors will vary between patients. 
Moreover, it is still unclear which factors are the key components of autologous serum. Nonetheless, in 
the absence of other tear substitutes containing epitheliotrophic factors, autologous serum can be 
considered as the current gold standard in this treatment approach, and a valuable therapeutic option for 
severe DED. 
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IV.B.1.b.  Nerve growth factor (NGF) 
Regeneration of innervation is an important consideration for restoring ocular surface 
homeostasis, which is regulated coordinately by neural inputs and other components of the integrated 
lacrimal functional unit. As detailed elsewhere in this report, the pathologic processes of DED (e.g., 
inflammation, hyperosmolarity) can alter corneal sensitivity and disrupt the lacrimal functional unit, thus 
reducing tear secretion and tear film stability (see Section III.A, Pathophysiology of DED). Significantly 
lower corneal subbasal nerve density has been observed in non-Sjögren DED compared with age-
matched controls.384 Direct injury to the corneal nerves, which can occur in various ocular procedures, 
also can disrupt tear dynamics and/or cause neurotrophic keratopathy (see Section II.B, Surgery-induced 
DED). Indeed, almost half the patients who undergo laser in situ keratomileusis (LASIK) experience 
neuropathic symptoms of dry eye.385 
Specific and defined treatments must be developed in order to improve corneal nerve function 
and support regeneration of innervation. In this context, tear-like substitutions containing nerve growth 
factor (NGF) hold much potential for modulating corneal innervation and improving epithelial cell 
healing. In patients with neurotrophic keratopathy treated with autologous serum, the restoration of 
ocular surface epithelial integrity has been attributed to the NGF content of the serum.386, 387 In rats with 
capsaicin-induced corneal damage, NGF-containing eye drops improved Schirmer values, promoted 
corneal healing, and reversed corneal sensory denervation.388 This is further corroborated by a canine 
model of DED experimentally induced by bilateral lacrimal gland removal, in which topical application of 
NGF significantly improved all evaluated parameters compared to baseline values and control 
contralateral eyes, including keratopathy, corneal haze, conjunctival goblet cell density and impression 
cytology, Schirmer values, and corneal staining.389 
There is evidence that NGF also is involved in the modulation of tear function. In patients 
following refractive surgery, differences in six-month postoperative corneal sensitivity and sensations of 
ocular surface dryness were correlated with tear levels of NGF in the early postoperative period.85 In 
preclinical investigations, NGF has recently been shown to regulate conjunctival goblet cell secretion in 
rats.390 Upregulation of NGF has also been correlated with reduced corneal epithelial cell apoptosis after 
hyperosmolar stress in vitro, suggesting that NGF may promote recovery from hyperosmolarity-induced 
corneal damage.391 
Recombinant human NGF (rhNGF) has now been investigated clinically in patients with various 
ocular surface conditions. In patients with DED, rhNGF eye drops (4 or 20 μg/mL) have been tested in an 
open-label, monocentric Phase II study, to be completed in 2015.392 NGF is also being investigated in the 
REPARO Study, a Phase I/II randomized, double-blinded, multicenter trial evaluating the safety and 
efficacy rhNGF eye drops in patients with neurotrophic keratitis stage 2 (persistent epithelial defect) and 
stage 3 (corneal ulcer).393 Preliminary results from the Phase I segment demonstrated that the treatment 
was safe and well tolerated, and suggested favorable effects on healing of corneal lesions in the majority 
of patients with neurotrophic keratitis caused by diabetes, surgery, and viral infection.394 Promising 
preliminary results have also been obtained in patients with neurotrophic keratitis caused by chemical 
burns. 
 
IV.B.2.  Reconstruction/Regeneration of Secretory Tissue 
  Aqueous-deficient dry eye (ADDE) is a major class of DED, and mainly signifies lacrimal gland 
deficiency (Figure 8), although insufficient aqueous secretion by the conjunctiva may also underlie 
ADDE.68 However, most efforts to restore secretory tissue in severe DED have focused on lacrimal gland 
reconstruction or regeneration, and have involved several approaches. 
 
IV.B.2.a.  Salivary gland transplantation 
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One approach of lacrimal gland replacement involves heterotopic salivary gland transplantation. 
Various glands have been used for this purpose, such as the major salivary glands (e.g., the 
submandibular gland)297, 395 and minor salivary glands.298 This method is capable of restoring 
seromucinous secretions (with submandibular gland transplantation) as well as the aqueous tear film 
layer, and significant improvements are seen in Schirmer values, FBUT, corneal staining, and symptoms 
of discomfort. However, vision is not affected; moreover, it is important to note that the osmolarity of 
saliva is very different than tears. In fact, the hypoosmolar salivary secretions can induce a microcystic 
corneal edema, which can in turn lead to epithelial defects. Thus, lacrimal gland replacement is only for 
selected patients with end-stage DED with absolute aqueous tear deficiency. 
 
IV.B.2.b.  Lacrimal gland reconstruction 
Tissue engineering for lacrimal gland reconstruction is still very much experimental, as the 
reconstruction of a complex functional secretory tissue (such as the lacrimal gland) poses several 
challenges. As with virtually all bioengineered tissues, cells first need to be isolated, then expanded in 
sufficient clinical-grade quantities, and characterized to ensure function. Finally, cells need to be grown in 
functional quantities on biocompatible, three-dimensional matrices that ensure mechanical stability and 
bioavailability. Excellent reviews on strategies and tools for tissue engineering have been published,396, 
397 and techniques have been described for isolating and culturing lacrimal gland epithelial cells.398, 399 
Secretory function can be tested using the ß-hexosaminidase assay.400 Briefly, ß-hexosaminidase activity 
is a biomarker for lysosomes and is an established test for acinar cell secretion. Enzymatic activity of ß-
hexosaminidase is measured in the cell culture supernatant at baseline and after parasympathetic 
stimulation (usually with carbachol or phorbol esters). Work by our group401 and others have focused on 
developing model constructs for lacrimal gland reconstruction. A simulated microgravity environment402 
as well as a lacrimal gland in vitro model based on decellularized lacrimal gland tissue403 have been 
developed, and facilitate the development of three-dimensional constructs containing functional acinar 
cells with secretory responses to carbachol. Hirayama et al. recently bioengineered fully functional 
lacrimal gland replacements by transplantation of a bioengineered organ germs.299 These recent 
advances represent great strides toward the goal of lacrimal gland replacement for DED. 
 
IV.B.3.  Reconstruction/Regeneration of the Ocular Surface 
In severe cases of ocular surface disease or injury, reconstruction of the ocular surface is often 
necessary to prevent corneal opacity and recurrence of the disease. Approaches for reconstructing and 
regenerating the ocular surface range from established grafting techniques to promising possibilities 
from advances in tissue engineering. 
 
IV.B.3.a.  Amniotic membrane transplantation 
For reconstructing the ocular surface, the amniotic membrane is the most commonly used matrix; 
this approach is simple and most reliable, and can promote healing of the ocular surface in spite of severe 
tear film deficiencies.404 The amniotic membrane possesses many characteristics that directly address 
the pathophysiology of DED: it can act as a supportive substrate for epithelial cells; it has anti-
inflammatory properties; and the amnion harbors various growth factors (e.g., NGF, TGF-ß, KGF, EGF) 
that are beneficial for ocular surface repair and regeneration. 
The amniotic membrane can be used in various ways for corneal surface reconstruction. As an 
inlay graft (typically for sterile ulcers), one or more layers of amniotic membrane can integrate into the 
cornea—filling stromal defects and acting as a basement membrane for the epithelium.405 As a protective 
onlay (typically for epithelial defects), the amniotic membrane acts as a natural bandage contact lens to 
support epithelial closure, and usually falls off after 1–2 weeks. A sandwich technique, combining both 
onlay and inlay grafts, can be used for severe ocular surface defects. 
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The amnion also may be used for conjunctival reconstruction, however with some limitations. 
Efficacy of conjunctival reconstruction is dependent on whether the bulbar conjunctiva or the fornix has 
to be restored: for the bulbar conjunctiva, results are typically favorable, whereas in fornix 
reconstruction, fornix depth is often lost.406 Oral mucosa transplantation can be combined with amniotic 
membrane for reconstruction of the conjunctiva, with the amnion mostly used for the bulbar conjunctiva 
and the more bulky and stable oral mucosa for tarsal reconstruction. 
While amniotic membrane has many advantages for ocular surface reconstruction (mostly relating 
to its elastic, basement membrane, anti-inflammatory, and epitheliotrophic properties), there are some 
drawbacks. Transparency can be variable, often limiting best-corrected visual acuity to 6/60. There also 
may be variability in tissue properties and epitheliotrophic factors, depending on donors and storage 
methods. Furthermore, highly inflamed ocular surfaces may result in quick enzymatic digestion and loss 
of membranes. Finally, disease transmission is an inherent concern with allogeneic transplants. Thus, 
there is a need for the development of new matrices to standardize mechanical properties and growth 
factor content. 
 
IV.B.3.b.  Bioengineered ocular surface substitutes 
Many of the potential limitations of both autologous and allogeneic grafts may be circumvented 
with bioengineered tissue grafts. These can be produced in a highly controlled, standardized, and scalable 
manner, with high potential for growth factor integration. 
Equine type I collagen membranes showed satisfactory re-epithelialization after ocular surface 
reconstruction in rabbits, and thus may be suitable for corneal surface reconstruction in patients with 
persistent, nonhealing ulcerations.407 As transparency is an important concern in corneal surface 
reconstruction, keratin matrices made of human hair may serve as suitable matrices for corneal epithelial 
progenitor cells. Chemically processed and gamma sterilized, the keratin matrix is displays excellent 
transparency in vitro, suitable biomechanical properties, and good surgical applicability in suturing to 
the ocular surface.408, 409 In biocompatibility experiments in a rabbit model, keratin films exhibited 
excellent transparency and served as a good surface for limbal epithelial cell growth.410 These 
bioengineered matrices may have clinical utility for reconstructing the corneal surface. 
While there are few reports in the scientific literature on bioengineered conjunctival substitutes, 
modified poly(lactide-co-glycolide) (PLGA) scaffolds have been investigated in vivo for reconstruction of 
conjunctival wounds.411 PLGA/collagen scaffolds were grafted for four weeks, and exhibited complete 
epithelialization and reduced scarring/contraction. However, this type of scaffold lacks elasticity, which 
poses a problem for reconstructing the fornix. Conjunctival tissue substitutes based on compressed 
collagen gels may be useful for this purpose; these serve as good substrates for conjunctival cells and 
display favorable biomechanics due the compression process, resulting in very good surgical handling.412 
While much of the work on ocular surface bioengineering is still in the preclinical stage (particularly for 
conjunctival reconstruction), there are many exciting developments that may lead to future clinical trials 
and integration into the management for severe DED. 
 
IV.B.3.  Summary and Conclusions 
For the treatment of severe DED, there have been dramatic developments in the areas of tear-like 
substitution, regeneration of secretory tissues, and ocular surface reconstruction. The key factors of 
existing treatments have to be identified in order to develop new more effective therapies—particularly 
in addressing the specific causes of DED and mechanisms of damage. Ongoing research on NGF and other 
neurotrophic and epitheliotrophic factors may yield new possibilities for targeted treatment of DED 
subtypes. The growing fields of regenerative medicine and tissue engineering offer promising new 
approaches, particularly for lacrimal gland regeneration and reconstruction, as well as reconstruction of 
the ocular surface. 
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IV.C.  Regulatory Issues Associated with the Development of a DED Drug in Europe (Gary D. 
Novack, PhD) 
 Although DED is a significant global problem and the focus of ample research and development, 
very few pharmacologic treatments have achieved regulatory approval in limited markets. In the 2010 
TFOS/ARVO Symposium on Global Treatments for DED, barriers were identified in the development of 
pharmacotherapies for DED. As noted in the published report from that symposium in 2012, there were 
no pharmacological approvals in Europe.413 In a 2014 article, Dr. Novack noted that Restasis® was 
approved in some Eastern European countries.414 In the present meeting (2015), Dr. Novack reviewed 
regulatory issues in gaining regulatory approval in Europe for pharmacological treatment of DED. 
 
IV.C.1.  European Medicines Agency Workshop on Medicines for Eye Disorders 
 In October 2011, the European Medicines Agency (EMA) hosted the inaugural Workshop on 
Clinical Development and Scientific Advice in Ophthalmology.415 This workshop gathered experts from 
academia, industry, and regulatory agencies to review the regulatory and scientific challenges in 
developing medicines for eye disorders. One session was dedicated to DED, and featured a review of new 
therapeutic approaches and challenges for the treatment of DED by Dr. David Sullivan,416 an update of the 
TFOS MGDW by Dr. Kelly Nichols,417 and an overview of ocular surface biomarkers and inflammation by 
Prof. Anthony Bron.418 Additionally, industry perspectives were provided by Dr. Auli Ropo of Santen,419 
and regulatory perspectives by Dr. Kerstin Wickström of the Swedish Medical Products Agency (MPA).420 
 In her presentation, Dr. Wickström noted that there were no centrally approved pharmacological 
therapies for DED in the EU, although oral pilocarpine has been approved for symptomatic treatment of 
dry eyes in Sjögren's syndrome via the mutual recognition procedure (MRP). Also used are oral 
bromhexine and evening primrose (Oenothera glazioviana). 
 European submissions also require a pediatric investigation plan to be submitted relatively early 
in the development process. This is a non-trivial plan, as well as typically a non-trivial clinical trial to 
conduct. 
 
IV.C.2.  Recent European Approval 
 On January 23, 2015, the EMA’s Committee for Medicinal Products for Human Use (CHMP) 
adopted a positive opinion recommending marketing authorization for Santen’s Ikervis® (cyclosporine 
1% emulsion), and marketing authorization (valid throughout the European Union) was issued March 19, 
2015.421 The indication is “treatment of severe keratitis in adult patients with DED, which has not 
improved despite treatment with tear substitutes.” At the time of the meeting (March 21, 2015), efficacy 
results underlying the approval were not available. Subsequently, that data became available on the 
EMA’s website (July 2015). The Sponsor conducted two randomized, vehicle-controlled double-masked 
studies, with the acronyms of SANSIKA (12 months) and SICCANOVE (6 months). 
 In SANSIKA, the primary outcome was a co-primary evaluation of signs and symptoms. A small but 
statistically significant difference in CFS improvement was observed between the treatment groups at 
Month 6 in favor of the active (mean change from baseline in CFS -1.05 with IKERVIS and -0.82 with 
vehicle, p=0.009). The mean change from baseline in ocular discomfort score (assessed using a Visual 
Analogic Scale) was -12.82 with IKERVIS and -11.21 with vehicle (p=0.808). 
 
IV.C.3.  Regulatory Advances in Other Major Markets 
 As of the time of the meeting, there had been no regulatory approvals for pharmacological 
treatment of DED since 2012 in either the U.S. or Japan. In 2012, lifitegrast ophthalmic solution 
demonstrated efficacy in the OPUS-1 Phase III clinical trial.353 A new drug application (NDA) for lifitegrast 
was submitted by Shire in 2015 to the U.S. Food and Drug Administration (FDA). 
 
IV.C.4.  Current Status and Perspective 
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 The regulatory status of pharmacological therapies for DED is major markets as of March 2015 is 
shown in Table 17. 
 By way of perspective in the risks of pharmaceutical development, Dr. Novack cited a 2010 report 
of all investigational compounds that entered clinical testing between 1999 and 2004. In this analysis 
based upon confidential data provided to the authors, only 16% eventually gained marketing approval.422 
A second report assessed the reasons for U.S. FDA rejection of initial NDAs. The major reasons were 
deficiencies in efficacy, safety, or chemistry.423 
 In a recent interview, Dr. Timothy J. Garnett, Chief Medical Officer and Senior Vice President of Eli 
Lilly & Company, maintained that inadequate attention to dosing during Phase 2 testing may result in 
costly dose finding (and increased risk of failure) in Phase 3 trials.424 Studies on pharmacokinetics and 
pharmacodynamics are relatively uncommon in ophthalmology compared to other fields of medicine, and 
pharmacogenomics is virtually nonexistent for DED.414 
 
IV.C.5.  Summary and Conclusions 
With the 2015 approval of Ikervis®, there is now a regulatory precedent in Europe. As noted 
previously by Novack (2014),414 development of a pharmacological treatment for dry eye is risky, and 
dependent upon having the right drug, the right dose, the right disease (i.e. patient selection) and the 
right endpoints. Fortunately, ophthalmology continues to be an area of investment,425 and thus it is 
hopeful that new pharmacotherapies will have the opportunity to be developed. 
 
V. SUMMARY (Kelly Nichols, OD, MPH, PhD) 
In the closing session, Dr. Nichols expressed gratitude to TFOS—particularly Amy Sullivan, 
Executive Director—for coordinating and raising funds for the meeting; and Dompé for generous 
financial support. The speakers, moderators, panelists, and attendees were also thanked for sharing their 
insight and fostering collective intellectual curiosity. Dr. Nichols highlighted key statements from the 
presentations and panel discussions to provide a global summary of the meeting; identify recurring 
themes among the diverse topics; and emphasize important areas of investigation towards meeting the 
unmet needs in dry eye treatment. 
 
V.A.  Scope of the DED Problem 
Over 20 large-scale, population-based studies have demonstrated clearly that DED is a global issue 
with prevalence ranging from approximately 8–50%, depending on the population(s) studied and the 
diagnostic criteria and questionnaires used. However, there is a striking lack of consensus on a minimum 
diagnostic battery, which becomes an even greater concern as it carries over from the clinic into clinical 
trials. 
Treatment options remain limited for patients, and even newly approved therapies merely 
represent expansion of markets for existing treatments. More therapeutic options are urgently needed; 
additionally, management protocols must integrate education and prevention in order to deliver 
treatment to a broader clinical audience. 
Incidence and natural history data are still lacking for DED, and ongoing research may improve 
the identification and classification of the disease state. Existing surveys and questionnaires have many 
limitations in terms of monitoring changes over time or with intervention. A persistent problem is the 
lack of correlation between signs and symptoms of DED. 
Various ophthalmic procedures (e.g., refractive surgery, trabeculectomy, and cataract surgery) are 
known to induce DED; conversely, DED can affect surgical outcome. Thus, greater consideration of ocular 
surface health is needed in the arena of ocular surgery. Nonetheless, surgically induced dry eye is a 
promising model in which to study causative etiologies, diagnosis, and disease management. Contact lens 
discomfort may also be a promising model for studying dry eye pathogenesis, particularly as it affects 
50% of contact lens wearers and represents a two- to three-fold higher odds ratio for DED. 
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V.B.  Clinical Challenges of DED 
The clinical challenges of DED include its pathophysiology and symptomology, which collectively 
drive diagnosis. While it is clear that modifiable environmental factors are important in dry eye 
pathophysiology, there is still a lack of consistent evidence to convince clinicians and patients alike to 
address these factors. 
Nonetheless, advances in the understanding of core pathological mechanisms may lead to 
improved diagnosis and management. Tear osmolarity is emerging as a meaningful diagnostic measure, 
and the forthcoming DEWS II presents an opportunity to systematically assess the existing osmolarity 
data in order to make reliable recommendations. Other emerging concepts also promise to drive the 
reciprocal translation between clinical and scientific investigation. These include Marx’s line position in 
the diagnosis of MGD; compositional changes in the tear lipid layer; and the improved understanding of 
ocular surface innervation and nerve responses associated with dry eye symptomology, osmolarity, 
blinking, and tearing. 
The definition and classification of DED is a continuing clinical challenge for diagnosis and 
management. Of note, the overlap between ADDE and EDE warrants re-exploration of the impact of 
evaporation on DED subtypes and their diagnosis. It is abundantly clear that DED is not a single disease, 
but rather multiple interrelated and overlapping conditions with distinct etiologies. Therefore, specific 
targeted treatments are needed for the various subtypes of DED. Accordingly, these targeted treatments 
require specific test batteries and clinical trial designs—reemphasizing the need for a minimum set of 
diagnostic criteria for DED, and perhaps distinct tests for screening and diagnosis. 
 
V.C.  Treatment Challenges of DED 
Despite dozens of clinical trials and therapeutic candidates at some level of development, there 
are only three pharmacologics approved for the treatment of dry eye in limited markets. It continues to 
be difficult to demonstrate efficacy for dry eye therapeutics in clinical trials. In this regard, considerations 
include the precision of the diagnostic batteries, the suitability of the study designs (i.e., reflecting the 
mechanism of action of the candidate therapeutics), and the relevance of the outcome measures. 
 Nonetheless, there is encouraging research on novel approaches for treating DED, particularly for 
patients with severe and end-stage disease. Significant advances have been made in the study of 
autologous serum and specific neurotrophic factors with the aim of supporting ocular surface healing and 
regeneration. There are also innovative surgical approaches for reconstructing and regenerating the 
ocular surface, reconstruction of secretory tissue, and transplantation of amniotic membranes or 
bioengineered tissues. Continued investigation and investment in DED, combined with a newly 
established therapeutic precedent in Europe, suggests that the global market is verging on new 
pharmacologic treatments. 
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Figure Legends 
 
Figure 1. Classification of contact lens discomfort.(Reprinted with permission from Nichols KK, Redfern 
RL, Jacob JT, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the definition 
and classification subcommittee. Invest Ophthalmol Vis Sci 2013;54:TFOS14-19. Copyright: Association 
for Research in Vision and Ophthalmology.) 
 
Figure 2. The proposed composition of the human tear film. (Reprinted with permission from The 
International Workshop on Meibomian Gland Dysfunction. Invest Ophthalmol Vis Sci 2011;52:1917-2085. 
Copyright: Association for Research in Vision and Ophthalmology.) 
 
Figure 3. Fluorescein-stained, lower tear meniscus with arrowheads indicating the mucocutaneous 
junction at the peripheral apex of the meniscus, and arrows indicating peripheral and central boundaries 
of the “black line” above the central apex of the meniscus. (Adapted from Bron AJ, Yokoi N, Gaffney EA, 
Tiffany JM. A solute gradient in the tear meniscus. I. A hypothesis to explain Marx's line. Ocul Surf. 2011 
Apr;9(2):70-91.) 
 
Figure 4. Mechanisms of dry eye. (Reprinted with permission from DEWS Definition and Classification 
Subcommittee. The definition and classification of dry eye disease: report of the Definition and 
Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92.) 
 
Figure 5. Predicted natural history of A) aqueous-deficient dry eye (ADDE) for a typical etiology such as 
non-Sjögren’s syndrome dry eye, and B) (EDE) for a typical etiology, such as meibomian gland 
dysfunction (MGD). Clinical events are represented on the left, and time progresses toward the right (top 
row). (Reprinted with permission from Bron AJ, Yokoi N, Gafney E, Tiffany JM. Predicted phenotypes of 
dry eye: proposed consequences of its natural history. Ocul Surf. 2009;7:78-92.) 
 
Figure 6. Graphical summary of the qualitative sensations of the ocular surface (left), the classes of 
ocular surface sensory neurons and their major transducing channels (center), and the specific stimuli 
(right). (Modified from Belmonte C, Acosta MC, Merayo-Lloves J, Gallar J. What Causes Eye Pain? Curr 
Ophthalmol Rep. 2015;3:111-21.) 
 
Figure 7. Graphical summary of the potential effects of pathological processes on ocular surface sensory 
nerve terminals and evoked sensations. Right: Inflammation activates polymodal nociceptor fibers, 
causing sensitization and inflammatory pain; in contrast, inflammation tends to inhibit TRPM8-
dependent impulse activity in cold thermoreceptors. Left: injury of polymodal nociceptors can cause 
temporal aberrations in activity and neuropathic pain, whereas injury in cold thermoreceptors can result 
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in sensations of cooling, dryness, discomfort, and pain. (Reprinted with permission from Belmonte C, 
Acosta MC, Merayo-Lloves J, Gallar J. What Causes Eye Pain? Curr Ophthalmol Rep. 2015;3:111-21.) 
 
Figure 8. A) Schematic illustration of the relationship between DED and other ocular surface disorders. 
B) Subtypes of DED (right) and potential environmental factors (left). It is important to note that the 
various subtypes are not mutually exclusive and may coexist. (Reprinted with permission from: 2007 
Report of the International Dry Eye WorkShop (DEWS). Ocul Surf. 2007;5:65-204.) 
 
Figure 9. The five-grade pictorial “Meiboscale” for grading and classifying meibomian gland loss. Image 
courtesy of Heiko Pult, MSc, PhD, and available at www.heiko-pult.de. 
 
Figure 10.The interacting pathways in meibomian gland dysfunction (MGD). The core mechanisms of 
obstruction (via epithelial hyperkeratinization) with increased viscosity (of meibum) result in two 
effector limbs (arrows) that lead to low delivery of oil onto the lid margin and tear film, or via the 
atrophic pathway to a secondary low secretion of oil. Both effector arms result in evaporative dry eye. 
This process is based on underlying factors (shown in square colored boxes in the periphery) and 
influenced by associated functional complexes (shown on rounded colored areas). Vicious circles 
(indicated by red arrows) act back and can reinforce the pathological process into a self-propagating 
disease, if not limited by timely diagnosis and therapy. (Reprinted with permission from: Knop E, Knop N, 
Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of 
the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest 
Ophthalmol Vis Sci. 2011;52:1938-78. Copyright: Association for Research in Vision and Ophthalmology.) 
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Ophthalmology Service, Centre François-Xavier Michelet, Bordeaux and Past-
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Sydney, Australia 
James Wolffsohn, OD, PhD (Speaker) 
Deputy Executive Dean and Deputy Dean of Life and Health Sciences at Aston 
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Table 2. Nomenclature and Symptoms of DED 
Nomenclature 
Dry eye disease 
Dry eye disorder 
Dry eye syndrome 
Dry eyes 
Dysfunctional tear syndrome 
Keratoconjunctivitis sicca (KCS) 
Non Sjögren's KCS 
Sicca syndrome 
Sjögren's KCS 
Xerophthalmia/xerosis 
Symptoms 
“Chilli powder in my eyes”* 
“Dust in my eyes”* 
Burning* 
Discomfort* 
Dryness* 
Gritty/sandy eyes* 
Itching 
Pain 
Fatigue 
Tearing or watery eyes 
Visual aberrations 
*May represent different symptoms or different terms used to express of the same 
symptom as patients may use different words to describe the same sensation as 
determined by their vocabulary and past experience. 
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Table 3. Global Prevalence of Dry Eye, 2015: Summary of population-based 
studies 
Location, Study Reference Year Prevalence 
(gender) 
Africa, Nigeria 35 2014 19.2% (overall) 
Asia, China (Beijing Eye Study) 24 2009 21.0% (overall) 
Asia, China—Mainland 31 2014 17.0% (overall) 
21.6% (females) 
Asia, China—Southeast 38 2015 9.5% (overall) 
Asia, Eastern India—West Bengal 30 2012 26% (overall) 
Asia, Iran 34 2014 8.7% (overall) 
Asia, Japan (Koumi Study) 28 2011 12.5% (males) 
21.6% (females) 
Asia, Japan (high school students)  22 2008 21.0% (males) 
24.4% (females) 
Asia, Japan (visual display 
terminal users) 
23 2003 26.9% (males) 
48.0% (females) 
Asia, Korea (Korea National Health 
and Nutrition Examination 
Survey) 
36 2014 8.0% (overall) 
Asia, Mongolia (Henan Eye Study) 26 2010 50.1% (overall) 
Asia, Singapore 37 2015 12.3% (overall) 
Asia, Singapore (Singapore Malay 
Eye Study) 
40 2010 6.5% (overall) 
8.2% (males) 
4.9% (females) 
Asia, Indonesia—Sumatra* 15 2002 27.5% (overall) 
Asia, Taiwan (Shihpai)* 16 2003 33.7% (overall) 
Asia, Tibet  21 2008 52.4% (overall) 
AUS (Extension Blue Mountains 
Eye Study)* 
18 2003 16.6% (overall) 
AUS, Melbourne* 13 1998 5.5% (overall) 
EU, Spain (Saines Eye Study) 25 2009 11.0% (overall) 
9.0% (males) 
11.9% (females) 
UK, Britain (TwinsUK) 32 2015 9.6% (females) 
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US, Wisconsin (Beaver Dam Eye 
Study)* 
14 2000 14.4% (overall) 
11.4% (males) 
16.7% (females 
US, Wisconsin (Beaver Dam 
Offspring Study) 
33 2014 14.5% (overall) 
10.5% (males) 
17.9% (females) 
US, Maryland—Salisbury* 12 1997 14.6% (overall) 
US (Physicians’ Health Study)† 19, 20 2009 4.34% (males) 
US (Veterans Affairs Population) 29 2011 12% (males) 
22% (females) 
US (Women’s Health Study)* 17 2003 7.8% (females) 
*Included in the 2007 TFOS DEWS report 
†Included in the 2007 TFOS DEWS report in abstract form 
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Table 4. Dry Eye Questionnaires published since the TFOS Dry Eye WorkShop 
(DEWS) 
Description Reference Year 
A questionnaire-based survey, Kanpur, India 45 2014 
Development and validation of the Dry Eye-Related 
Quality-of-Life Score questionnaire 
46 2013 
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) 47 2012 
Comparison of ocular-surface disease index 
questionnaire, tear film break-up time, and Schirmer 
tests 
48 2012 
Development and validation of the impact of dry eye on 
everyday life (IDEEL) questionnaire 
49 2011 
Validation of the 5-Item Dry Eye Questionnaire (DEQ-5) 50 2010 
McMonnies questionnaire: Rasch analysis 51 2009 
Symptom Assessment iN Dry Eye (SANDE) 
Questionnaire 
52 2007 
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Table 5. Dry Eye Trials Registered on ClinicalTrials.gov (2010) 
 
Primary Outcome(s) Number of Trials 
OSDI (n=13) or other Sx 19 
Staining 13 
Schirmer 6 
TBUT 4 
  
Design  
Interventional 48 
Observational 9 
  
Phase  
I 3 
II 12 
III 6 
IV 16 
Not listed 20 
  
Interventions (n=48)  
Oral 5 
Topical 39 
Surgical or other 4 
  
Sponsor  
Industry 39 
University/Government 18 
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Table 6. Grading Level of Evidence of Clinical and Basic Research Studies 
Clinical studies 
 Clinical Studies Basic Science 
Level I Evidence obtained from at least 1 properly 
conducted, well- designed randomized 
controlled trial or evidence from studies 
applying rigorous statistical approaches  
Well-performed studies 
confirming a hypothesis 
with adequate controls 
published in a peer-
reviewed journal  
Level II Evidence obtained from 1 of the following: 
• Well-designed controlled trial without 
randomization 
• Well-designed cohort or case-control 
analytic study from 1 (preferably 
more) center(s) 
• Well-designed study accessible to 
more rigorous statistical analysis 
Preliminary or limited 
published study  
Level 
III 
Evidence obtained from 1 of the following: 
• Descriptive studies 
• Case reports 
• Reports of expert committees 
• Expert opinion 
• Meeting abstracts, unpublished 
proceedings 
Meeting abstracts or 
unpublished presentations 
Adapted from: Papas EB, Ciolino JB, Jacobs D, et al. The TFOS International 
Workshop on Contact Lens Discomfort: report of the management and therapy 
subcommittee. Invest Ophthalmol Vis Sci 2013;54:TFOS183-203. 
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Table 7. Summary of Evidence Supporting Various Potential Management Strategies for CLD 
 
Treatment Strategy 
Level of Supporting Evidence 
I II III 
Adjust replacement frequency  †  
Change material  *  
Add internal wetting agents  *  
Add external wetting agents  † † 
Eliminate the care system  †  
Alter lens design factors † ‡ † 
Change the care system  †  
Use tear supplements, wetting agents, lacrimal inserts  †  
Dietary supplementation (omega-6 FAs/evening primrose oil) †   
Punctal occlusion  † † 
Topical medication (azithromycin)  †  
Improve environment   † 
Alter blink behavior  *  
Switch soft to RGP lens  *  
Switch RGP to soft lens  †  
Orthokeratology  *  
Refractive surgery  *  
Spectacles   †, ‡ 
* Insufficient or contradictory evidence 
† Soft contact lenses 
‡ Rigid contact lenses 
Blank cells indicate no data available. 
Adapted from: Papas EB, Ciolino JB, Jacobs D, et al. The TFOS International Workshop on Contact Lens 
Discomfort: report of the management and therapy subcommittee. Invest Ophthalmol Vis Sci 
2013;54:TFOS183-203. Copyright: Association for Research in Vision and Ophthalmology. See source for 
details. 
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Table 8. Treatments Targeting Symptoms of Discomfort 
Treatment  Potential Effects 
Prosthetic Replacement of the Ocular 
Surface Ecosystem (PROSE) 
Scleral lens device to maintain a reservoir of tears to wet and 
lubricate the ocular surface267, 268 
Acupuncture Possible effects on dry eye signs and symptoms, as compared to 
sham-treated controls or artificial tears269-271 
ShengJinRun ZaoYangXue granules Improve tear flow and reduce dry eye symptoms272 
Korean red ginseng Improve tear film stability and reduce dry eye symptoms273 
Suppressing transient receptor 
potential vanilloid 1 (TRPV1) receptor 
Decrease pain associated with DED274 
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Table 9. Treatments Targeting Mucin Deficiency 
Treatment  Potential Effects 
Galectin 3 Stabilize ocular surface mucins; promote corneal wound 
healing276 
Mycophenolate mofetil Increase MUC5AC277 
DA-6034 (Eupatilin) Stimulate MUCs 1, 2, 4, 5AC, 5B & 16278 
Trefoil factor family peptide 3 (TFF3) Stabilize mucous layer 279, 280 
Nerve growth factor & mimetics Increase goblet cell number and MUC5AC production; increase 
corneal sensitivity; promote corneal epithelial wound healing281, 
282 
Tamarind seed polysaccharide Mimic the mucoadhesive mucin properties283-286 
Nanoparticles Deliver plasmids coding for MUC5AC protein to the ocular 
surface287, 288 
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Table 10. Treatments Targeting Aqueous Tear Deficiency  
Treatment  Potential Effects 
Tear film supplements (e.g., albumin, 
alginic acid in contact lenses, 
autologous serum, cationic oil 
emulsion, chitosan, chondroitin 
sulfate/xantham gum, hyaluronate, 
hydroxypropyl-methylcellulose, 
hydroxypropyl-guar, n-acetyl-
aspartyl-glutamic acid, phospholipids, 
propylene glycol, selenoproteins) 
Improve physical properties of the ocular surface (e.g., wetting, 
lubrication; many clinical studies and trials have been 
completed, or are underway, to evaluate these supplements)292 
Oral sea buckthorn oil Reduce tear osmolarity293 
7eye (Panoptyx) Provide hydration via moisture chamber glasses 
Botulinum toxin injection near lower 
puncta  
Prevent tear drainage and alleviate the clinical manifestations of 
severe DED294, 295 
Salivary gland transplantation Replace dysfunctional lacrimal gland 296-298 
Generation of two- and three-
dimensional lacrimal gland constructs 
for lacrimal gland regeneration 
Serve as bioengineered lacrimal gland replacement299 
Oculeve electrode device Stimulate the lacrimal nerve to induce aqueous tear 
production300-302 
Oral anethole triothine Increase Schirmer wetting score303 
Oral uridine Stimulate tear and mucin secretion after metabolism into P2Y2 
agonist304 
Oral hydroxychloroquine Increase Schirmer wetting score in in Sjögren’s syndrome 
patients with anti-fodrin antibodies305 
Oral pilocarpine and cevimeline Reduce subjective eye symptoms in Sjögren’s syndrome 
patients, with no effect on tear volume306-308 
Lacritin and synthetic derivatives Promote basal tearing309, 310 
Abdominal (diaphragmatic) breathing Increase tear meniscus volume311 
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Table 11. Treatments Targeting Epithelial Cell Desiccation 
Treatment  Potential Effects 
Betaine Reduce apoptosis, hyperosmotic stress, and expression of 
proinflammatory cytokines313-317 
Ectoine Fluidize lipids and reduce evaporation318 
Erythritol Reduce hyperosmotic stress and expression of proinflammatory 
cytokines313, 314, 316, 317 
L-carnitine Reduce hyperosmotic stress and expression of proinflammatory 
cytokines313, 314, 316, 317 
Taurine Reduce inflammation-related proteins319 
Trehalose Prevent desiccation-induced corneal epithelial cell death320, 321 
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Table 12. Treatments Targeting Mitochondrial Oxidation 
Treatment  Potential Effects 
plastoquinonyl decyltriphenyl 
phosphonium (SkQ1; visomitin) 
Decrease mitochondria-generated ROS during aging and reduce 
apoptosis of ocular surface epithelial cells322, 323 
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Table 13. Treatments Targeting Inflammation 
Treatment category Potential Effects 
Omega 3 fatty acid supplementation Alter tear metabolic profile;325 decrease tear evaporation rate;326 
improve TBUT and Schirmer scores327 
Resolvins  Metabolite of omega-3 fatty acids; reduce corneal epithelial 
barrier disruption and goblet cell loss 
Glucocorticoids  
Dexamethasone & transscleral 
iontophoresis 
 
Mapracorat   
Loteprednol  
Fluorometholone  
Difluprednate  
Non-steroidal anti-inflammatory 
drugs (e.g., bromfenac, diclofenac and 
pranoprofen)  
Inhibit cyclooxygenases 1 and 2 and promote mucous 
production 
Calcineurin inhibitors  Immunosuppression via inhibition of calcineurin 
Tacrolimus (Prograf)  
Cyclokat® (0.1% cyclosporine)  
Cationic emulsions  
Pimecrolimus (Elidel)  
Antibodies  
Secukinumab Neutralize IL-17α 
ESBA105 Inhibit TNF-α 
Belimuma Inhibit B cell activation factor (BAFF) 
VAY736 Inhibit BAFF-receptor 
Canakinumab anti-IL-1β 
Tocilizumab anti-IL-6 receptor 
Baminercept Inhibit lymphotoxin-β and LIGHT pathway 
Abatacept Inhibit T cell activation 
Other anti-inflammatory drugs  
Lifitegrast (SAR 1118) Bind to LFA-1 and prevent ICAM-1 interaction, inhibiting 
adhesion, migration, proliferation, and cytokine release 
CAN-FITE-101  Oral adenosine3 receptor agonist; induce inflammatory cell 
apoptosis 
Regenerx RGN259 () Topical thymosin β4 
Perceiva  Sirolimus, subconjunctival injection, inhibit response to IL-2 
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Tofacitinib Inhibit Janus kinase 3 
EBI-005 Antagonize IL-1 receptor signaling 
Cis-urocanic acid Reduce inflammation and free radicals 
DNase Remove neutrophil extracellular traps 
XG-104 Inhibit c-Jun N-terminal kinase, T cell differentiation and 
cytokine production 
R932348 Inhibit Janus kinase 3 and Syk kinase 
Mesenchymal stem/stromal 
cells 
Suppress inflammation 
FK506 binding proteins Inhibit cytokine production 
SB203580 Decrease lacrimal gland inflammation 
Rivoglitazone & WY14643 Bind to PPARs 
Cilomilast Phosphodiesterase 4 inhibitor 
DA-6034 Inhibit NF-κB activation 
Chitosan-N-acetylcysteine 
conjugate 
Thiolated polymer; suppress inflammation, no effect on corneal 
staining 
Tranilast Inhibit lipid mediator and cytokine release 
N-acetyl aspartyl glutamic acid Neuropeptide, antiinflammatory 
Astaxanthin  Oral carotenoid, antiinflammatory 
Curcumin Natural polyphenol extracted from turmeric, antiinflammatory 
Catechins From green tea, antiinflammatory 
KLS-0611 & KCT-0809  Treat surface damage, antiinflammatory 
Mimetogen MIM-D3 Tyrosine kinase TrkA receptor agonist328 
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Table 14. Treatments Targeting MGD 
Treatment  Potential Effects 
Lipid-based tear substitutes Promote lipid spreading, lubrication and tear stability, and 
reduce tear evaporation 
Intraductal probe Remove the terminal duct obstruction 
Eyelid warming devices (e.g., 
LipiFlow®, Blephasteam®, 
Eyegiene®, MGDRx EyeBag®, 
MediBeads®, warm compresses) 
Alleviate meibomian duct obstruction by improving eyelid 
hygiene (warming and humidifying the eyelid to liquefy 
meibum)337-346 
Intense pulsed light (IPL) Warm meibomian secretions; decrease inflammatory cytokines 
and microbial growth347-349 
Topical testosterone Decrease hyperkeratinization of the terminal duct, stimulate 
meibomian gland function and increase the quantity and quality 
of meibum162, 336 
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Table 15. Treatments Targeting Ocular Surface Stress 
Treatment  Potential Effects 
Lubricin Decrease ocular surface friction and stress in DED7, 8 
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Table 16. Summary of Recent Dry Eye Trials that Failed to Meet Corneal Staining Endpoints 
 
Compound Mechanism of Action Company Result 
Lifitegrast Small-molecule 
integrin inhibitor; 
ICAM-1 decoy 
SARcode Bioscience, 
Shire 
Results of the OPUS-1 trial (presented 
in 2012) met primary endpoint of 
change from baseline in inferior 
corneal staining score vs. placebo 
(p=0.0007), and showed significantly 
reduced corneal fluorescein staining 
(superior and total) and conjunctival 
lissamine staining vs. placebo;353 
however, top-line results of the OPUS-2 
trial did not meet co-primary endpoint 
of change from baseline in inferior 
corneal staining score (p=0.6186 vs. 
placebo)354 
CF101 A3 adenosine receptor 
agonist 
OphthaliX Inc. 
(subsidiary of Can-
Fite BioPharma, 
Ltd.) 
Did not meet primary efficacy endpoint 
of complete clearing of corneal 
staining355 
Diquafosol 
tetrasodium 
2% (Prolacria) 
Purinoreceptor P2Y(2) 
receptor agonist; 
promotes tear and 
mucin secretion by 
increasing intracellular 
Ca2+ concentrations 
Inspire 
Pharmaceuticals 
Did not achieve significance of the % of 
patients with complete corneal 
staining clearance (primary p = 0.526) 
or its secondary endpoint of a two-unit 
reduction in staining (p = 0.368)260 
RGN-259 
[Thymosin 
beta 4 (Tβ4)] 
Promotes cell 
migration; increases 
cell adhesion via 
increased laminin-5 
production; anti-
apoptotic and anti-
inflammatory 
RegeneRx 
Biopharmaceuticals 
Did not meet all pre-specified primary 
outcome measures including inferior 
corneal and conjunctival staining356-358 
Bromfenac 
(REMURA™) 
Cyclooxygenase 1 and 
2 inhibitor 
ISTA 
Pharmaceuticals, 
Inc. 
Staining was not statistically better 
than placebo in the entire patient 
cohort359 
EGP-437 Novel formulation of 
dexamethasone 
phosphate delivered 
iontophoretically 
Eyegate 
Pharmaceuticals, 
Inc. 
Primary efficacy endpoints of corneal 
staining and ocular discomfort were 
not achieved360 
RX-10045 Synthetic analog of 
RvE1, a resolvin with 
anti-inflammatory and 
cell-sparing activities 
Resolvyx 
Pharmaceuticals, 
Inc. 
There was a significant reduction in 
CAE-induced staining from baseline, 
but the change was not significantly 
different than placebo (p=0.11)361 
MIM-D3 TrkA receptor agonist 
(NGF mimetic) 
Mimetogen 
Pharmaceuticals Inc. 
Pre-specified primary outcome 
measures of fluorescein corneal 
staining and worst symptom scores 
over 28 days were not met328 
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EBI-005 Interleukin-1 (IL-1) 
receptor blocker 
Eleven 
Biotherapeutics, Inc. 
Differences from baseline in change in 
total corneal fluorescein staining and 
patient-reported ocular pain and 
discomfort based on the ocular surface 
disease index (OSDI), were not 
statistically significant when compared 
to patients who received vehicle 
control362 
R348 Ophthalmic JAK/SYK 
inhibitor 
Rigel 
Pharmaceuticals, 
Inc. 
Failed to meet changes in corneal 
fluorescein staining, conjunctival 
staining, tear production, and dry eye 
symptom scores from baseline over 12 
weeks of treatment vs. placebo363 
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Table 17. Regulatory Status of Therapies for DED 
 Country/Region (Year Approved) 
Product USA Canada Japan Europe 
Cyclosporine Restasis® 
(2002) 
Restasis® 
(2010) 
 Ikervis® 
(2015) 
Hyaluronic 
Acid* 
--- --- Hyalein® 
(1995) 
--- 
Diquafasol --- --- Diquas® 
(2010) 
--- 
Rebamapide --- --- Mucosta® 
(2011) 
--- 
Modified from Sullivan DA, Hammitt KM, Schaumberg DA, et al. Report of the 
TFOS/ARVO Symposium on global treatments for DED: an unmet need. Ocul Surf. 
2012;10:108-16. 
 
